The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

12-2011

THE CYTOPLASMIC TAIL OF MHC CLASS I MOLECULES PLAYS A
CRITICAL ROLE IN DENDRITIC CELL-INDUCED T CELL IMMUNITY
Tania G. Rodriguez-Cruz

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Immunity Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Rodriguez-Cruz, Tania G., "THE CYTOPLASMIC TAIL OF MHC CLASS I MOLECULES PLAYS A CRITICAL
ROLE IN DENDRITIC CELL-INDUCED T CELL IMMUNITY" (2011). The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open
Access). 243.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/243

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

THE CYTOPLASMIC TAIL OF MHC CLASS I MOLECULES PLAYS A
CRITICAL ROLE IN DENDRITIC CELL-INDUCED T CELL IMMUNITY

by

Tania G. Rodríguez-Cruz, B.S.

APPROVED:

Gregory Lizee, Ph.D.
(Supervisory Professor)

Patrick Hwu, M.D.

Stephanie Watowich, Ph.D.

Stephen Ullrich, Ph.D.

Willem Overwijk, Ph.D

APPROVED:

Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

THE CYTOPLASMIC TAIL OF MHC CLASS I MOLECULES PLAYS A
CRITICAL ROLE IN DENDRITIC CELL-INDUCED T CELL IMMUNITY

A
DISSERTATION
Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
M.D. Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of

DOCTOR OF PHYLOSOPHY
By
Tania G. Rodríguez-Cruz, B.S.

Houston, Texas
December, 2011

ii

DEDICATION

I dedicate this dissertation to my parents, Carmen and Ricardo, and to my brother,
Omar, for all their support throughout my life and for inspiring me to achieve my goals,
even though it meant being physically away from them.

I would also like to dedicate this dissertation to my grandparents for their infinite
love, kindness, life lessons, and for the great food. I also want to dedicate this dissertation
to all my aunts, uncles, and cousins for the humor, comfort and for the wonderful
childhood memories. Thanks for helping me to become the person I am today. This is for
all of you…

iii

ACKNOWLEDGEMENTS

I want to acknowledge with great gratitude, several people whose involvement and
support made it possible to complete this journey. First and foremost, my deepest
appreciation goes to my advisor, Dr. Greg Lizee for accepting me in his laboratory,
challenge me, and believing in me. His guidance and supervision throughout all these
years have been instrumental for my career development. I would also like to express my
sincere appreciation to Dr. Patrick Hwu for all his support and scientific advice throughout
these years.
My sincere appreciation also goes to my supervisory committee members, Dr.
Stephanie Watowich, Dr. Stephen Ullrich and Dr. Laurence Cooper, for their invaluable
intellectual guidance, support and feedback regarding my research work and for constantly
challenging me to become a better scientist. I would also like to extend my appreciation to
other members of my advisory and examination committees, Dr. Michel Gilliet, Dr. Gilbert
Cote, Dr. Willem Overwijk, for their important contribution to my training.
I would like to also acknowledge all the present and past members of the
laboratory. In particular, to Dr. Shujuan Liu, Dr. Jahan Khalili, Dr. Weiyi Peng, Mayra
Cantu, Dr. Brian Rabinovich, Dr. Yanyan Lou, Yan Yang, Jessica Chacon, for their
support, and helpful scientific discussions.
My genuine appreciation goes to the University of Texas Health Science Center
Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center for providing
me with cutting-edge education that will serve as the foundation of my career as a scientist.

iv

I want to thank the National Institute of Health for providing the financial support
during my PhD training through a ROI supplement (R01-CA111999-S1). I am also grateful
to our collaborators Dr. Willem Overwijk and Dr. Laura Johnson for providing with mice
and cell lines.
I firmly believe that no Ph.D. can be achieved without friends who provided
support and encouragement through these years. I want to thank my friends, Dr. Guadalupe
Reyes, Dr. Guillermo Armaiz, Dr. Luis Vence, Dr. Chantal Bernabetch and Jessica De
Orbeta for their emotional support during my training and for their many valuable life and
career advices.
Last, but not least, I would like to thank all my friends who stood by my side all
these years. First, I want to thank my high school and college friends Emy, Odemaris, Rina,
Rebeca, and Carissa, for the many wonderful memories, the laughs and for still being part
of my life. I also want to thank my friends and family from Houston for helping me in
maintaining a balanced and fun life. I will be forever thankful for having you in my life.

v

THE CYTOPLASMIC DOMAIN OF MHC CLASS I MOLECULES PLAYS A
CRITICAL ROLE IN DENDRITIC CELL-INDUCED T CELL IMMUNITY

Publication No.
Tania Giselle Rodríguez-Cruz, Ph.D.
Supervisory Professor: Gregory Lizee, Ph.D.

The presentation of MHC class I (MHC-I)/peptide complexes by dendritic cells
(DCs) is critical for the maintenance of central tolerance to self and for the regulation of
cytotoxic T lymphocytes (CTL)-mediated adaptive immune responses against pathogens
and cancer cells. Interestingly, several findings have suggested that the cytoplasmic tail of
MHC class I plays a functional role in the regulation of CTL immune responses. For
example, our previous studies demonstrated that exon 7-deleted MHC-I molecules (Δ7) not
only showed extended DC cell surface half-lives but also induced significantly increased
CTL responses to viral challenge in vivo. Although the Δ7 splice variant of MHC class I
does not occur naturally in humans, the animal studies prompted us to examine whether
exon 7-deleted MHC-I molecules could generate augmented CTL responses in a
therapeutic DC-based vaccine setting. To examine the stimulatory capacity of Δ7 MHC
class molecules, we generated a lentivirus-mediated gene transfer system to induce the
expression of different MHC-I cytoplasmic tail isoforms in both mouse and human DCs.
These DCs were then used as vaccines in a melanoma mouse tumor model and in a human
invitro co-culture system.

vi

In this thesis, we show that DCs expressing exon 7-deleted MHC class I molecules
(Δ7-Db), stimulated remarkably higher levels of T-cell cytokine production and
significantly increased the proliferation of melanoma-specific (Pmel-1) T cells compared
with DCs expressing wild type MHC-I. We also demonstrate that, in combination with
adoptive transfer of Pmel-1 T-cell, DCs expressing Δ7-Db molecules induced greater antitumor responses against established B16 melanoma tumors, significantly extending mouse
survival as compared to DCs expressing WT- Db molecules. Moreover, we also observed
that human DCs expressing Δ7-HLA-A*0201 showed similarly augmented CTL
stimulatory ability. Mechanistic studies suggest that Δ7 MHC-I molecules showed
impaired lateral membrane movement and extended cell surface half-lives within the
DC/T-cell interface, leading to increased spatial availability of MHC-I/peptide complexes
for recognition by CD8+ T cells. Collectively, these results suggest that targeting exon 7
within the cytoplasmic tail of MHC class I molecules in DC vaccines has the potential to
enhance CD8+ T-cell stimulatory capacity and improve clinical outcomes in patients with
cancer or viral infections.
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CHAPTER 1- INTRODUCTION

1.1 The immune system: Overview
The immune system has evolved many different mechanisms to make rapid, highly
specific and often protective responses against a wide variety of pathogens, including
bacteria and viruses. In fact, the tragic example of severe immunodeficiencies as seen in
some congenitally-determined diseases and in acquired immunodeficiency syndrome
(AIDS), illustrates the critical role of the immune system in protection against pathogenic
microorganisms [1; 2]. After a century of much debate as to whether the immune system
can eliminate tumor cells, strong evidence now suggests that the cellular immune system
plays a critical role in the control of tumorigenesis [3; 4] The cellular immune system not
only plays a role in the elimination of pathogens and cancer cells, but it also plays a role in
the development of several clinical conditions, including autoimmune diseases (i.e. Type 1
diabetes, Lupus), allergies and rejection of transplanted tissues [5; 6; 7; 8]
The cells of the immune system originate from hematopoetic stem cells and are
constantly re-circulating throughout the body for detection of invading pathogens or tumor
cells. In vertebrates, immune defenses consist of two connected systems: innate and
adaptive immunity. Cells from the innate immune system express receptors that are
evolutionary conserved and recognize pathogen-associated molecular patterns (PAMPs),
which are shared by common microorganisms. This conserved receptor-mediated
recognition leads to the capture and fragmentation of pathogens into small antigenic
proteins, accompanied by inflammation and in many cases pathogen clearance. The cells
mainly responsible for these functions are macrophages and dendritic cells [9; 10]
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Cells from the adaptive immune system are characterized by their ability to
specifically recognize a wide range of pathogens and to generate long-lasting memory that
provides improved protection against re-infection. The adaptive immune responses are
mediated by T and B lymphocytes, which express highly diverse antigen specific receptors.
In contrast to the evolutionary-conserved receptors found in innate immune cells, the T-cell
receptor (TCR) and the B-cell receptor (BCR) are generated by gene rearrangements,
which provide each single lymphocyte with a unique specificity. B lymphocytes eliminate
extracellular pathogens by producing antibodies [9; 10]. T lymphocytes are divided into
two major categories: CD4+ T cells and CD8+ T cells. These types of lymphocytes are
known to specifically recognize antigens bound to the groove of MHC proteins, which are
encoded by a large complex of genes called the major histocompatibility complex (MHC)
[11]. There are two main structurally and functionally distinct classes of MHC proteins:
class I MHC proteins and class II MHC proteins. CD4+ T cells recognize antigens bound
to MHC class II. This type of T-cell lymphocyte have the ability to help or inhibit the
development of specific types of immune responses, including antibody production and
increased microbidicial activity of macrophages. In contrast, CD8+ T lymphocytes
recognize antigens bound to MHC class I molecules. This type of T-cell lymphocyte is
involved in direct effector functions such as the lysis of virus-infected cells or cancer cells
[11; 12]. For the purpose of this thesis, the biological functions of CD8+ T cells and their
roles in cancer immunity will be discussed in more details.
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1.2 T cells eliminate tumors and virally infected cells
The development of T cells begins with the migration of hematopoetic precursors
from the bone marrow to the thymus. At the thymus, hematopoetic precursors commit to
the T-cell lineage, which then undergoes thymic selection. Thymic selection of the T-cell
lineage is based on the recognition of self-peptide/MHC class I complexes at the cell
surface of thymic dendritic cells, and thymic medullary epithelial cells by the TCR of T
cells [13]. The binding properties of TCRs for their peptide/MHC ligands (i.e. affinity and
avidity rates) are critically important in not only T-cell thymic selection but also for full
activation of peripheral T-cell responses [14]. During thymic selection, TCRs with low
affinity for self-peptide/MHC leads to weak interactions promoting T-cell survival
(positive selection). However, TCRs with high affinities for self-peptide MHC complexes
leads to strong interactions promoting T-cell apoptosis (negative selection). Thymic
selection is important because it induces central tolerance by eliminating autoreactive Tcells with high affinity TCRs for self peptides and by selecting T-cells with low affinities
TCRs for self-peptides [14]. Having succeeded thymic selection, naive T cells (i.e. CD8+ T
cells) then exit the thymus and migrate to peripheral lymph nodes, where they become
activated into effector T cells that can kill target cells such as tumor cells and virallyinfected cells.
Naïve T cells are mainly found in peripheral lymphoid organs, and their activation
is initiated following the recognition of pathogen or tumor-associated antigens on the
surface of an antigen-presenting cell (APC), usually a dendritic cell. The antigen is in the
form of peptide fragments which are generated by the degradation of foreign protein
antigens within the proteosome or acidic compartments (i.e. endosomes) of the APC. The

3

peptide fragments are then transported into the endoplasmic reticulum (ER) for binding to
nascent MHC class I proteins. The affinity of the peptide for a specific MHC class I
molecule is critical for the formation of stable peptide/MHC class I complexes that can be
recognized by the TCR of the cognate CD8+ T cell. For example, it has been demonstrated
that peptides bound to MHC class I molecules with low affinity leads to low
affinity/avidity or weak interactions between the TCR-pMHC complexes resulting in
incomplete activation of the cognate T-cell. It has also been demonstrated that low affinity
binding of peptide to MHC can mediate the escape of autoreactive T cells from negative
selection [15].
T-cell activation requires two major types of signals: The first signal involves the
recognition of the peptide/MHC complex located on the surface of an APC by the TCR on
T cells. The second signal involves the triggering of co-stimulatory molecules (i.e. CD28,
CD80) and adhesion molecules (i.e. integrins, LFA-1) expressed on the cell surface of both
the APC and T-cell [12]. These signals lead to the stimulation of the TCR, which in turn
induces a signaling cascade (i.e. MAPK signaling) that promotes the differentiation of
naïve T cells into potent effector antigen-specific T cells, such as cytotoxic T cells (CTL)
[16].
The antigen recognition event for the generation of the first signal is a very
sensitive process since it has been demonstrated that as few as 1-50 pMHC complexes are
sufficient to activate target-cell lysis by CTLs [17]. Two models have been proposed to
explain how TCR-pMHC interactions result in T cell activation: the serial TCR
engagement and the kinetic proofreading model. The serial TCR engagement model
proposes that a single pMHC complex is able to serially trigger multiple TCR molecules
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since T cell activation can be accomplished at low physiological density of specific pMHC
complexes on the target cell surface [18]. This model is consistent with different studies
that have demonstrated that the TCR-pMHC interactions are of low affinity and have rapid
association and dissociation rates [19]. In conclusion, in order for few pMHC complexes to
efficiently trigger multiple TCRs, each individual TCR needs to bind and dissociate from
its ligand with fast kinetics to allow the next TCR to be triggered resulting in a sustained
TCR signal. On the other hand, the kinetic proofreading model proposes that a minimal
half-life for the TCR-pMHC interaction is an additional requirement for a complete TCR
signal [20]. According to this model, fast dissociation of the TCR from the pMHC complex
would result in incomplete TCR signaling preventing T cell activation. By contrast, a more
sustained interaction (slow dissociation rates) would allow complete TCR signaling and T
cell activation. In support of this model, different studies have reported that T cell
activation correlates with the half-life of the TCR-pMHC interaction [20]. However, it has
been recently demonstrated that for T-cell activation, both shortened and prolonged TCRpMHC interaction half-lives have detrimental effects on T cell activation [21]. Therefore, it
has been suggested that efficient T cell activation occurs within an optimal dwell-time
range of TCR-pMHC interaction. It has been described that such dwell-time for triggering
efficient T cell activation needs to be sufficiently long to complete the TCR signal cascade
but also short enough to allow serial engagement of multiple TCRs by a few cognate
pMHC complexes.
Once naïve CD8+ T cells are activated, they undergo clonal expansion and migrate
to peripheral tissues expressing the same peptide/MHC class I complex that induce their
activation. During clonal expansion, the initial numbers of antigen-specific precursors
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increase more than 1000-fold, generating a pool of effector T cells, which can directly kill
pathogen-infected cells or tumor cells [22]. The expansion phase usually lasts for 7 to 9
days. After the effector phase, the majority (90-95%) of antigen-specific T cells die
through a mechanism called apoptosis in order to maintain homeostasis. The surviving
cells form a stable memory pool that can generate more rapid and greater responses upon
secondary encounter with the antigen [23]. Activated T cells also secrete cytokines such as
interleukin-2 (IL-2) and interferon-γ (IFN- γ), which are known to not only promote T cell
expansion, but also enhance anti-viral and anti-tumor responses by up-regulating the
expression of MHC proteins on cancer cells or viral-infected cells [23; 24; 25]. Once
activated, CTLs migrate through the peripheral tissues where they may encounter cells
expressing the same foreign antigen that induced their activation and differentiation [12].
Upon antigen recognition on the target cell, CTLs utilize at least two mechanisms to
kill the target cell; both mechanisms operate by inducing the target cell to undergo
apoptosis, which is a highly evolutionary conserved mechanism of cell death that ensures
the elimination of “unwanted” cells from the body [26]. In order to kill target cells, CTLs
begin to secrete a pore-forming protein called perforin, which is known to polymerize at
the target cell surface to form transmembrane pores. Perforin is found in secretory vesicles
(i.e. CD107a+ vesicles) of the CTLs and is released by exocytosis at the point of contact
with the target cell [26; 27]. The secretory vesicles also contain granzyme B, which is a
protease that enters the target cell through the perforin-induced transmembrane pores and
activates caspase-induced apoptosis [27; 28]. A second strategy that CTL utilize to kill
target cells is through the interaction of Fas and Fas ligand. Fas is expressed on the target
cells while Fas ligand is expressed on the surface of CTLs. The interaction of Fas and
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FasL leads to a signaling cascade that activates downstream caspases and subsequent
apoptosis of the target cell [29].
Because of their extraordinary capacity to specifically recognize foreign antigens,
to migrate toward infected areas and to directly kill target cells, CTLs show great promise
in the development of therapeutic treatment for different diseases, including cancer and
viral infections. In fact, many studies have used CTLs to treat cancer patients and although
proven to induce anti-tumor responses, complete responses have been relatively rare [30;
31; 32]. However, one limitation is that the affinity of most TCRs specific for shared tumor
antigens is usually very low. Thus, different strategies have been developed to increase the
affinity and avidity of TCRs. For example, one study has demonstrated that removing Nglycosylation sites in the constant region of the TCR leads to enhanced avidity and
improved recognition of tumor cells by T cells [33]. Other studies have demonstrated that
specific mutations in the CDR3 domain of the TCR can control the TCR-pMHC interaction
half-lives leading to optimal T cell activation [21]. Another limitation is that CTLs do not
persist in vivo long enough to eradicate tumors [32]. In addition, cells within the tumor
microenvironment express or secrete inhibitory factors that downregulate the effector
functions of CTLs. To overcome these limitations, different studies have developed new
strategies. For example, in melanoma, the transfer of CTLs into lymphodepleted melanoma
patients results in objective clinical response rates as high as 50% [34]. Other strategies
such as vaccines plus adjuvants are currently being developed to increase T-cell
proliferation and effector functions [35; 36; 37].
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1.3 Dendritic cells are master regulators of T-cell immunity

The processing and presentation of peptides by dendritic cells (DCs) is critical for
the activation and differentiation of naïve T cells into effector cells [38]. DCs are
professional antigen presenting cells located in most tissues, where they capture, process
and display antigen-derived peptides on MHC molecules. Following antigen capture and
processing, DCs migrate to lymphoid organs, where they present peptide-MHC complexes
to T-cell antigen receptors (TCR) on naïve T cells. In conjunction with TCR triggering,
DCs can also engage co-stimulatory and cytokine receptors to influence T cell
proliferation, survival and effector activity.
There are different DC subsets with distinct cell surface markers and biological
functions. Three of the major DC subsets have been described in mouse: (1) CD11c+CD8DCs, (2) CD11c+CD8+ DCs and (3) CD11c+CD45RA+Gr1+ plasmacytoid DCs (PDCs)
[39]. The CD8-DCs have been described to be more efficient at capturing antigens and
displaying them on MHC class II molecules for recognition of CD4+ T cells. On the other
hand, the CD8+ DCs were demonstrated to be more efficient at capturing antigens and
displaying them on MHC class I molecules to promote CD8+ T cell responses [40; 41]. The
CD8+ DCs also have the unique capacity to capture dying cells and display exogenouslyderived antigens on MHC class I molecules, a process termed cross-presentation [41].
Because of their capacity to initiate CTL responses in vivo, CD8+DCs are the most logical
targets for vaccine development. In contrast to CD8-DCs and CD8+DCs, PDCs are the
main producers of Type I interferons, in particular interferon-α (IFN- α), which has been
shown to be important for the recruitment and activation of other immune cells into the
infected area to control disease [42]. In humans, two main DCs subsets have been
described: myeloid-derived DCs (CD11c+CD123-) and lymphoid-derived DCs or
8

plasmacytoid DCs (CD11c-CD123+) [39]. However, in contrast to mouse DC subsets, the
study of human DC subsets has been more challenging mainly because they only represent
less than 2% of total cell numbers in tissues, and blood monocytes are the main reliable
source of precursor cells [35; 43]. Both challenges are being overcome, and adequate DCs
numbers can now be generated from progenitors. One method to generate sufficient DC
numbers is by culturing hematopoetic stem cells from bone-marrow (CD34+) in the
presence of different cytokines [44]. Another method is to differentiate DCs derived from
human blood monocytes that have been cultured with GM-CSF and IL-4, followed by
activation in a monocyte-conditioned medium.
DCs need to undergo a process of activation in order to initiate potent T-cell
immune responses [38]. During steady state, DCs are mostly found in peripheral tissues as
immature DCs. Immature DCs (iDCs) are professional phagocytes that can internalize and
process antigens from pathogens for example. They express low levels of MHC molecules
(MHC class I and MHC class II), the glycoprotein CD83 and the co-stimulatory molecules,
CD86 and CD80, which are critical for efficient activation of T cells [38]. Because they
express low levels of CD80 and CD86, iDCs play an important role in the induction of
peripheral tolerance, a process required for protecting self tissues. However, upon
infection, danger signals from pathogens induce iDCs to undergo a differentiation program
called maturation. This maturation process transforms iDCs into potent activators of T-cell
mediated immune responses [45]. Danger signals are recognized by evolutionary conserved
receptors such as Toll like receptors (TLRs), which are abundantly expressed in DCs [46].
Upon recognition of danger signals, TLRs initiate a signaling cascade that induces iDCs to
upregulate MHC and co-stimulatory molecules at their cell surface and to secrete cytokines
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[38; 46]. Inflammatory cytokines, bacterial and viral products can also induce dendritic cell
maturation through direct interaction with receptors expressed on DCs [47]. In contrast to
immature DCs, mature DCs have low phagocytic activity but are remarkably efficient in
antigen presentation [38]. Mature DC are the most potent antigen presenting cell for
activating naïve T cells, in particular CD8+ T cells, to differentiate into cytotoxic antigen
specific T cells (i.e CTLs). This is mainly because mature DCs express high levels of
antigen presenting molecules (MHC class I and MHC class II) and co-stimulatory
molecules (CD80, CD86 and CD83) at their cell surface. They also secrete high levels of
interleukin-12 (IL-12), which is known to mediate the differentiation of CTLs [38].
DCs present peptides in the context of MHC class I molecules to CD8+ T-cells by
using two major pathways: (1) direct presentation, in which the cell itself is infected with
the antigen it presents on MHC-I; and (2) cross-presentation, in which the DCs engulfs
components of an infected cell and then processes and present the associated antigen bound
to MHC-I. [48]. However, a third mechanism -cross-dressing- has also been recently
postulated. This mechanism of antigen presentation involves DCs (acceptor) to acquire
peptide/MHC-I complexes directly from another infected APC allowing antigen
presentation by acceptor DC to occur rapidly, without the need of any antigen processing.
Moreover, Wakim and Bevan have recently reported that cross-dressing can activate
memory but not naive CD8+ T cells. One possible explanation for this may be that naïve T
cells, with their high activation threshold, disfavor cross-dressing because it involves the
presentation of vanishingly small number of peptide/MHC class I complexes. A more
detailed molecular description of these pathways is discussed in the MHC molecules
section.
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DCs have held great promise for use in vaccines aimed at enhancing pathogen or
tumor antigen-specific CTLs because of their high potency for initiating T cell-mediated
immune responses. However, several questions need to be addressed in the development of
effective vaccines that utilize DCs. These questions require a deep understanding of the
biological functions of DCs. For example: the first question to be addressed should be what
type T-cell mediated immune response is desired: CD4+ T cells or CD8+ T cells? Another
question to be addressed would be what type of DC subset to use for eliciting such an
immune response? Finally, what maturation signals are appropriate for activating DCs in
particular settings? In cancer settings, several DC vaccines have proven to be effective at
generating potent CTL-mediated antitumor responses [35]. Some of these vaccines
formulations are discussed below in the DC cancer vaccines section.
1.4 The role of MHC class I molecules in DC-induced T-cell immunity
MHC class I molecules are one of the two primary classes of proteins encoded by
the major histocompatibility complex (MHC), which were discovered to play a critical role
in tissue rejection and immunity against pathogens and tumors [25].

MHC class I

molecules are expressed by almost all nucleated cells and their main function is to display
peptides from intracellular proteins (i.e. viral or self proteins) to CD8+ T cells. However,
MHC class I molecules can also bind and present peptides from extracellular proteins (i.e.
apoptotic tumor cells) to CD8+ T cells, a process known to as cross-presentation [49].
Once the TCR of CD8+ T cells recognizes peptide/MHC class I complexes at the cell
surface of DCs, a T-cell signaling cascade is initiated that promotes the elimination of
abnormal or virus-infected cells.
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MHC class I molecules present peptides through two main pathways: the
endogenous or classical pathway and the cross-presentation pathway (See figure 1). The
presentation of intracellular-peptides through the endogenous pathway begins in the cytosol
of antigen presenting cells with the degradation of proteins, self proteins as well as those of
pathogens. Degradation occurs in the proteosome, which is a macromolecule with
proteolytic activity known to degrade cytosolyc proteins into small peptides fragments.
The resulting peptide fragments are then transported from the cytosol into the lumen of the
endoplasmic reticulum (ER) through the transporter associated with antigen processing
proteins (TAP). In the ER, peptides combine with nascent class I MHC proteins with the
help of ER-resident chaperons, such as calnexin, tapasin, calreticulin and Erp57 [49]. These
proteins are involved in the proper assembly of a complete receptor complex suitable for
transport to the cell surface. For example, calnexin is known to stabilize the MHC class I α
chains prior to β2-microglobulin binding [50]. Tapasin binds to MHC class I molecules and
facilitates the binding of MHC class I molecules to TAP, thus leading to enhanced peptide
loading and colocalization. MHC class I molecules lacking a bound peptide are extremely
unstable and requires the binding of the chaperones, calreticulin and Erp57. Once
assembled, the peptide/MHC class I complexes are then released from the quality-control
machinery of the ER and transported to the plasma membrane through the default secretory
pathway. The transport of MHC class I molecules through the secretory pathway involves
different prost-translational modifications of the MHC class I molecule, including
glycosylation [51]. Once the glycosylation process occurs, the MHC class I molecules are
transported to the plasma membrane, where they present peptides to CD8+ T cells,
followed by internalization, recycling and degradation through different endosomal
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compartments [52; 53]. On the other hand, cross-presentation is based on the uptake of
exogenous antigens by DCs via phagocytosis. It has been demonstrated that phagocytosis
of exogenous antigens (i.e. apoptotic tumor cells) is mediated by Cdc42 and Rac GTPases,
which trigger actin rearrangements, protrusions of membrane around the apoptotic body
and engulfment into a phagosome that then fuses with early endosomes for antigen
fragmentation [54] [49; 55; 56]. Once in early endosomes, exogenously-derived peptides
can be loaded onto recycling MHC class I molecules and then transported to the plasma
membrane via Rab dependent mechanisms as demonstrated by different studies [49; 54;
55]. Once at the cell surface, exogenously-derived peptides can be recognized by CD8+ T
cells. The fact that antigen loading occurs in endosomal compartments during crosspresentation, it has been suggested that the classical and cross-presentation pathways of
MHC class I are spatially separated [52] [56].

1.5 MHC class I internalization and endocytosis
The molecular mechanisms of MHC class I internalization via endocytosis have
been described by differing studies demonstrating that MHC class I molecules can be
internalized either via clathrin-coated pits or in a clathrin-independent manner [57; 58]. For
example, different electron microscopy studies have demonstrated that MHC class I
molecules can be found in clathrin coated vesicles (CCVs) [57]. Also other reports have
suggested that the cytoplasmic domain of MHC class I molecules contains a putative
tyrosine-based endocytic motif (YXXФ, Y=tyrosine, X= any amino acid and Ф =
hydrophobic amino acid) at position 320 of the cytoplasmic tail [59]. In fact, tyrosine 320
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point mutants of MHC class I showed internalization defects [60]. It has been demonstrated
that tyrosine-based endocytic motifs as well as dileucine-based motifs can be recognized by
specific adaptor and accessory proteins involved in the initial formation of clathrin-coated
vesicles (CCVs) [61]. The molecular players that regulate clathrin-mediated endocytosis
have been described. For example, it has been demonstrated that the adaptor protein-2
complex (AP-2) can recognize both tyrosine and dileucine-based motifs on the cytoplasmic
domain of cargo molecules (i.e. LDL, MHC-class I, transferrin receptor, CD3-γ) [62]. Such
interactions promote the formation of peripheral plasma membrane invaginations that are
then coated with clathrin. Several studies have demonstrated that clathrin polymerization at
sites of membrane invaginations is regulated by the adaptor molecule, AP180. AP180 is
known to recruit clathrin to PtdIns (4, 5)P2 zones in the membrane. Clathrin polymerization
is important because it initiates the formation of clathrin-coated vesicles (CCVs) neck,
which is then cut by the membrane accessory scission protein, dynamin [63]. Dynamin is a
large GTPase that forms a helical polymer around the CCV neck and upon GTP hydrolysis,
mediates the fission of the vesicle from the plasma membrane promoting the release and
intracellular transport of the CCVs containing cargo molecules (i.e. MHC class I) [64]. The
CCVs then fuse to early endosomal compartments, a process that has been demonstrated to
be Rab5 dependent [65]. Rab 5 is a small GTPase protein found at the plasma membrane
and in CCVs. It has been suggested that Rab5 directs the trafficking of CCVs from the
peripheral membrane to early endosomal compartments by binding to specific motor
proteins of the cytoskeleton (i.e myosin) and by interacting with the early endosomal
antigen (EEA-1) [65]. Such interaction leads the fusion of Rab-5 expressing CCVs to early
endosomes. Once in the early endosome compartment, clathrin-dependent cargoes can be
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sorted into lysosomes for degradation or into recycling endosomes for trafficking back to
the plasma membrane [64; 66; 67]. It has been demonstrated that membrane recycling of
clathrin-dependent cargoes is regulated by small the Rab GTPases proteins, Rab4 and
Rab11. While Rab 4 mediates the rapid recycling of clathrin-dependent cargoes from early
endosomes to the plasma membrane (rapid recycling), Rab11 mediates the trafficking of
clathrin-dependent cargoes from early endosomes into recycling endosomes. The recycling
endosomes then translocate to and fused with the plasma membrane in a Rab11a dependent
mechanism [67; 68].
However, internalization and endocytic recycling of MHC class I molecules can
also be regulated by a clathrin-independent pathway since inhibitors of the clathrindependent pathway (i.e. AP180 mutants, dynamin mutants) did not completely impair
MHC class I endocytosis [63]. Contrary to the clathrin-dependent pathway, clathrinindependent endocytic pathway requires the ADP-ribosylation factor 6 (ARF6), actin
polymerization and Rab22a GTPases for the initial formation of tubular membrane
invaginations and intracellular trafficking of vesicles containing cargo molecules (MHC
class I) [Radhakrishna, 1999 #15][69; 70]. ARF6 is a small GTPase that regulates
peripheral plasma membrane/endosomal trafficking by switching between its GDP and
GTP form [71; 72]. Previous studies have demonstrated that ARF6 is found to be in its
GTP form at the inner space of plasma membrane and that ARF6 GTP initiates the
formation of actin rich surface protrusions, which have been shown to be regulated by the
actin regulatory protein, HS1 [58; 73]. Inactivation of ARF6-GTP through hydrolysis,
signals ARF6-GDP expressing vesicles to be transported from the plasma membrane to
early endosomal compartments via membrane intermediates that are yet to be defined. One
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study demonstrates that excision of the ARF6 vesicles occurs in a dynamin-independent
process [69]. However, the molecules that regulate the excision of ARF6 vesicles from the
plasma membrane has not been described, but is very likely that it could be small GTPases.
Once in the early endosomal compartment, ARF6-dependent cargoes, encounter clathrin
dependent cargoes, however, their routes for membrane recycling are regulated by distinct
Rab proteins. For example, while Rab 4 and Rab 11 have been involved in clathrindependent endocytosis, Rab22a has been shown to allow the correct delivery of MHC class
I containing vesicles from recycling endosomes to the plasma membrane in a clathrinindependent manner [70]. The recycling of MHC class I containing vesicles to the plasma
membrane is also regulated by the conversion of ARF6 GDP to ARF6 GTP through
nucleotide change [68; 69]. Nevertheless, different internalization and recycling routes
regulate peptide-MHC class I complex cell surface expression leading to controlled T cell
activation. The different antigen presentation pathways and trafficking of MHC class I
molecules are summarized in Figure 1.
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Figure 1. Antigen presentation and endocytosis of MHC class I molecules. Endogenous
peptides (green squares) enter the ER via TAP and bind to nascent MHC class I molecules.
Stable peptide-MHC class I complexes exit the ER and are transported to the plasma
membrane through the secretory transport pathway. At the plasma membrane, pepitdeMHC class I complexes are recognized by cognate CD8+ T cells and then internalized via
clathrin-dependent (mediated by AP-2, dynamin and Rab5) and/or ARF6-dependent
endocytosis. The peptide-MHC class I complexes then recycle to the plasma membrane via
different Rab proteins. On the other hand, exogenous antigens (orange) are phagocytosed
via Rho-a GTPases into early endosomal compartments, where they can be degraded by
early endosomal proteases (i.e. cathepsins) and loaded onto recycling MHC-I. They can
also be degraded by the proteosome and transported into early endosomes via endosomal
TAP. The pMHC complexes are then transported to the plasma membrane for crosspresentation to CD8+ T cells.
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1.6 Role of the MHC-I cytoplasmic tail
Many distinct MHC class I loci have been described in both humans and mice. In
humans, functional genes have been found for the HLA-A, -B, -C, -E, -F, and –G in the
short-arm of chromosome 6 [74]. In mice, MHC class I molecules are encoded by the H2K, D and L loci on chromosome 17. The products of the different MHC class I loci show
distinct tissue distributions and regulation of expression. For example, the HLA-A, -B and
–C products are expressed on a wide variety of somatic cells, with the highest expression in
hematopoetic cells. HLA-G is expressed by throphoblasts in the fetus [75]. Each human
gene is highly polymorphic. For example, there are more than 800 known variants of HLAB genes, more than 500 variants of HLA-A genes, and more than 100 variants of HLA-C
genes. The high diversity of MHC class I molecules is of critical significance because it
ensures the presentation of a very wide variety of peptides to CD8+ T cells. Expression of
MHC class I molecules can be regulated by several cytokines such as IFN-γ and TNF-α.
For example, several studies have shown that MHC class I molecules can be highly
upregulated in several different cell lines following the addition of IFN-γ and/or TNF- α to
the culture [49].
The crystal structure of a MHC class I molecule (HLA-A2) was first described in
1987 by Bjorkman and co-workers [76]. The three-dimensional structure of class I
molecules demonstrated that MHC class I are heterodimers consisting of a 44-kd α chain
noncovalently bound to a 12-kd soluble polypeptide called β2-microglobulin, which is not
encoded by the MHC locus (See figure 2). The class I α chain is composed of three
extracellular domains (α1, α2, and α3), a transmembrane segment, and a short cytoplasmic
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tail. Portions of the alpha chain are highly variable, with the polymorphisms located mainly
in the in the α 1 and α 2 domains. The α1 and α2 domains associate closely to form a deep
groove that constitutes the binding sites for antigenic peptides. They also constitute the
binding sites for the T-cell receptor [77]. By contrast, the amino acid sequence of the α3
domain is mostly conserved. It interacts with β2-microglobulin and also serves as binding
site for the CD8 co-receptor, which facilitates the interaction of T cells with MHC class I
molecules. The peptides that associate with MHC class I molecules are characterized by
having preferential anchor residues, which are important for binding to specific MHC class
I alleles [78; 79]. For example, HLA-A2 binds peptides that almost always have a leucine
residue in the second position and a valine residue in the last position, while the other
residues are highly variable [76]. Many different peptides can be presented by a particular
class I MHC protein since a few of the residues are crucial for MHC-I binding. Thus, a
tremendous repertoire of peptides can be presented by these molecules to T cells.
Different studies have demonstrated that the ~35 amino acid short cytoplasmic tail
of MHC-I plays a critical role not only in intracellular trafficking but also in DC-mediated
antigen presentation and CTL activation [80; 81]. The cytoplasmic tail of MHC class I is
encoded mainly by two separate exons (6 and 7), both containing a number of highly
conserved motifs (See figure 3) [80]. The biological function of the MHC class I
cytoplasmic tail was demonstrated by different groups using various cytoplasmic tail
mutants of MHC class I [80; 82; 83]. One study revealed that deletion of the entire MHC-I
cytoplasmic tail resulted in a complete abrogation of anti-viral CTL responses in vivo [51].
Other studies demonstrated that the tyrosine residue (Tyr-320) located in exon 6 is a
putative endocytic motif that is required for appropriate MHC-I trafficking through DC
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endosomal compartments, cross-presentation of exogenous antigens, and anti-viral CTL
priming [60; 80]. By contrast, deletion of exon 7-encoded cytoplasmic amino acids results
in increased anti-viral CTL responses in vivo [80]. Interestingly, it has been shown that
several species including mice, chickens and bovine, naturally express exon 7-deleted
MHC class I variants [84; 85; 86]. Such splice variants lack at least one conserved serine
phosphorylation site, Ser-335, and have been shown to exhibit delayed internalization in a
number of cell types, including DCs [80; 87]. However, in contrast to Tyr-320-mutated
MHC-I, MHC class I molecules lacking exon 7 maintain their ability to recycle through
DC endosomal compartments, and appear to be fully functional at binding and presenting
both endogenous and exogenous antigens [80; 88].

The intracellular trafficking of MHC class I molecules in different cell types is
regulated by its own cytoplasmic tail. For example, different studies have shown that wildtype (WT) surface MHC class I proteins are rapidly internalized and recycled through
endocytic compartments of both human and mouse DCs. This process is cytoplasmic taildependent and limits the surface half-life of MHC-I/peptide complexes for recognition by
CD8+ T cells [88]. Since MHC class I molecules lacking exon 7 were demonstrated to have
increased cell surface half-lives in DCs, we hypothesized that expression of MHC class I
molecules lacking exon 7 might lead to superior antigen presentation and therefore more
efficient CTL activation. In this thesis we tested this hypothesis by comparing the relative
capacity of WT and 7 MHC-I molecules to stimulate antigen-specific CTL responses in a
DC-based vaccine setting.
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Figure 2: Elements of the MHC class I cytoplasmic tail show a high degree of
evolutionary conservation. The cytoplasmic tail of MHC class-I is mostly composed of
exon 6 and exon 7. Alignment of the amino acid sequences derived from the MHC class I
cytoplasmic tail of widely divergent species reveals absolute conservation of amino acids
(red arrows). Tyrosine 320 (highlighted in yellow) and Serine 335 (highlighted in green)
are two highly conserved amino acids. Colors depict acid R-group charge characteristics:
yellow, hydrophobic; blue, polar and uncharged; red, positively charged; and grey,
negatively charged.
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1.7 Skin cancer: Melanoma
Cancer is a complex disease that causes millions of deaths worldwide and therefore
has been classified as a major problem in public health [89]. Many cancers develop when
DNA damage leads to different mutations that promote cells to grow out-of-control [90].
Among all types of cancers, non-melanoma skin cancer is the most common type of cancer
in the United States with more than 2 million people being diagnosed every year [91].
Non-melanoma skin cancer is divided into basal cell carcinoma and squamous cell
carcinoma; both being less life-threatening and significantly more common than
melanoma. Although melanoma only represents approximately 4% of all skin cancers,
epidemiological studies have demonstrated that it causes approximately 75% of deaths
related to skin cancer mostly due to its increased metastatic potential [92]. In the past 3
decades, the incidence of melanoma has increased dramatically, with Caucasians and men
older than 50 years old being at a higher risk of developing metastatic melanoma.

Melanoma usually appears as an existing mole that begins to change color, size or
morphology. This type of skin cancer develops from the uncontrolled growth of
melanocytes, which are mostly located in the bottom layer of the skin‟s epidermis but can
also be found in the middle layer of the eye, the inner ear, bones, intestines, and heart [93].
Melanocytes are the major producers of melanin, which is a ubiquitous dark pigment
responsible for the color of skin and hair. The main function of melanin is to protect the
skin from ultraviolet light-induced radiation which can cause serious mutations in the
DNA. If the mutations are not repaired by the DNA repair machinery, melanocytes begin to
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grow abnormally and may become malignant cells that can eventually lead to the
development of melanoma [94].

Although there are different melanoma risk factors including family history and
genetics, the largest melanoma risk factor is the prolonged exposure to ultraviolet rays
(UV) from the sunlight and tanning beds. Ultraviolet rays are classified into UV-A
(400 nm–315 nm), UV-B (315 nm–280 nm) and UV-C (280 nm–100 nm). However, UVassociated skin carcinogenesis studies have revealed that UV-B radiation accounts for
about two-thirds of melanoma cases [94]. Mechanistic studies have shown that UV-B
radiation causes mutations in genes involved in cell proliferation, differentiation and death.
For example, specific mutations in the BRAF gene (i.e. mutation V600E), which is
involved in cell growth, lead to the progression of melanoma as demonstrated by DNA
screening analyses in human samples These DNA screening studies determined that
approximately 60% of melanoma cases are associated with V600E BRAF [95]

Melanoma can be detected by using different methods including X-rays, PET
scans, CT scans and ultrasound. Detection at earlier stages is highly important for better
prognosis [96]. The progression of melanoma is divided into different stages based on
tumor size, ulceration, metastatic potential and survival rates [97]. Patients diagnosed with
stage 0 or melanoma in situ have abnormal melanocytes in their epidermis that may spread
to adjacent normal tissues if not surgically removed. If the disease is diagnosed and treated
at this early stage, there is almost 100% chance of survival. Patients with stage I have
developed melanoma in the epidermis and dermis of their skin but it has not spread to
nearby lymph nodes The tumor size at this stage is approximately less than 2mm and the
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survival rate is 85-99%. The most common treatment for this stage is surgical removal of
the tumor. If the tumor is not surgically removed during stage I, then the tumor may
continue to grow and develop ulceration. Ulceration is a negative prognostic factor for
patients with stage II melanoma and is associated with the presence of epidermis in the
tissue overlying the tumor [96; 97]. Patients diagnosed with this stage have a 40-85%
survival chance after treatment. Stage III melanoma is characterized by tumors that have
spread or metastasize to nearby lymph nodes. Patients diagnosed with stage III melanoma
have about 30-60% survival chance after treatment. During stage IV melanoma, cancer
cells have spread to other organs including distant lymph nodes, skin, liver, brain and
lungs. Patients diagnosed with stage IV have only a 10-20% survival chance after
treatment. The chance of survival is increased when the tumor is diagnosed and treated at
early stages [96; 97].

Melanoma, in contrast to other types of cancer, is highly immunogenic. In the past
two decades, many different melanoma-associated antigens have been described and
demonstrated to be specifically recognized by the immune system [32]. Based on these
findings, many studies aim to use the cellular immune system for the treatment of
melanoma since conventional chemotherapy regimens only leads to 10% of clinical
responses [98]. The treatment for melanoma includes surgical removal of the tumor,
chemotherapy, radiotherapy, immunotherapy or a combination of these treatments [96].
Different immunotherapy regimens for the treatment of melanoma and other types of
cancers are discussed in the next section.
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1.8 Cancer Immunotherapies
The concept of Immunotherapy evolved from early murine studies demonstrating
that the immune system can recognize and eliminate pathogens and tumors with high
specificity.

Immunotherapy refers to any approach that utilizes the patient‟s natural

immune defense system as a treatment for different diseases, including autoimmune
disorders, infectious diseases and cancer [30]. Immunotherapy for cancer was first
introduced by William B. Coley in the nineteenth century. In his studies, he observed
tumor regression and even disappearance following injections of a vaccine containing
bacterial extracts in and around tumors [99]. Based on many of his seminal observations,
different cancer immunotherapy methods are currently under development with the main
purpose of enhancing the body's natural immune defense to specifically recognize and
eliminate tumor cells. The main advantage of using immunotherapies, is that they are
specifically targeted to only eliminate malignant cells and not normal cells resulting in
lower toxicity levels compared to those induced by many chemotherapy regimens [100].

However, there are many barriers to be overcome in the development of cancer
immunotherapy.

The concept of Immune survilliance was not widely accepted until

experimental models demonstrated that lymphocytes spontaneously migrate to tumors and
there, they collaborate to control tumor growth in inbred mice [30]. However, tumor cells
and their microenvironment have evolved different mechanisms to favor tumor outgrowth
despite immune survilliance. One strategy is that tumor cells, in contrast to normal cells,
become more resistance to cell death or apoptosis in conditions where nutrition and oxygen
supplies are limited [101; 102]. Another strategy is that tumor cells have the ability to
regulate the expression of critical molecules involved in the induction of immune
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responses. For example, tumor cells downregulate the expression of MHC and costimulatory molecules while upregulating co-inhibitory molecules such as PD-L1 and PDL2, which suppress the effector function of T cells [103; 104; 105]. Also, cells within the
tumor microenvironment, including stromal cells and fibroblasts, secrete high levels of
inhibitory factors, such as interleukin-10 (IL-10) and tumor growth factor-β (TGF- β) [101;
102]. Inhibitory immune cells including T regulatory cells (Tregs), immature dendritic cells
and myeloid-derived suppressor cells (MDSC) have also been found in the tumor
microenvironment and play a critical role in the regulation of immune responses. All of
these barriers within the tumor microenvironment suppress the function of anti-tumor
specific T cells, leading tumor escape and progression of tumorigenesis. However, many
different clinical strategies have now been developed to block or suppress the negative
activity of the tumor microenvironment, and therefore boost antigen-specific T cell
mediated anti-tumor immunity [105].

Immunotherapy for cancer is divided into two categories: Passive immunotherapy
and active immunotherapy. Passive immunotherapy involves the generation of immune
components in the laboratory that are eventually administered into patients in order to
provide immunity against tumors. One advantage of using passive immunotherapy is that it
does not require the patient‟s immune system to take an active role in the elimination of
tumors. Thus, such immunotherapy is preferred when the patient‟s immune system is
highly compromised due to large tumor burdens or previous therapies. One disadvantage of
this approach is that tumors may become resistant to this therapy as the cancer cells mutate
or downregulate surface expression of targeted antigens [30].By contrast, active
immunotherapy usually involves the generation of vaccines to stimulate the patient‟s own
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immune system to fight cancer. One major advantage of using this type of immunotherapy
is that it can induce both therapeutic immunity (in the form of tumor-specific effector T
cells) and protective immunity (in the form of tumor specific memory T cells that can
control tumor relapse) [100]. Different examples of current immunotherapy regimens are
illustrated below.

CANCER IMMUNOTHERAPY
PASSIVE
ACTIVE
Monoclonal antibodies:
Antigen-specific vaccines:
 Anti-CD20 (Rituximab) for
 Peptide vaccines
Non-Hodgkin‟s Lymphoma.
 DC vaccines
 Anti-CTLA-4 (Ipilimumab) for
 Tumor lysates
Melanoma
 Anti-HER2 (Herceptin) for
Antigen non-specific vaccines:
breast cancer
 IFN-α
Adoptive T-cell Transfer:
 IL-2
 Ex vivo–engineered T cells
 TNF-α
(CARs)
 TILs
The use of monoclonal antibodies is an example of passive immunotherapy.
Monoclonal antibodies are molecules engineered in the laboratory that specifically
recognize particular targets on cancer cells (i.e. tumor antigens) [106]. Monoclonal
antibodies can be administered into patients intravenously. Once monoclonal antibodies
recognize cancer cells it can lead to disruption of cancer cell growth, or to increase antitumor immunity. One example of a monoclonal antibody currently used to treat B-cell
lymphomas resistant to other chemotherapy approaches is Rituximab [107]. Rituximab was
approved by the FDA in 1997 based on its safety and effectiveness in clinical trials. This
monoclonal antibody binds to the CD20 molecule on B cells. CD20 has been described to
regulate cell proliferation, and blocking its activity using rituximab leads to elimination of
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malignant B cells. Another example of a FDA-approved monoclonal antibody to treat the
most aggressive type of breast cancer (HER2+ breast cancer) is Herceptin [108; 109].

The use of immune cells such as T cells with anti-tumor activity is another example
of passive immunotherapy. Since the discovery that T cells can kill tumors, different
approaches have been developed for adoptively transferring tumor specific T cells into
cancer patients [31; 32]. This approach requires the isolation of T cells from the patient‟s
tumor followed by the progressive ex vivo expansion of those tumor-specific autologous T
cells using high concentrations of IL-2. The main purpose of the ex vivo expansion is to
increase the number of tumor-specific T cells with potent anti-tumor function for
subsequent infusions into patients. Although early clinical studies were disappointing,
recent reports have demonstrated that prior lymphodepletetion using chemotherapy
increases the anti-tumor activity of the infused T cells, resulting in approximately 50%
objective clinical responses in patients with metastatic melanoma [110].

One example of active immunotherapy is the use of vaccines. Vaccines have been
widely used to boost the immune system‟s natural ability to protect the body against
pathogens that may cause disease. Based on the same principles used to generate vaccines
against infectious agents, several therapeutic anti-cancer vaccines have been developed for
the treatment of different cancers, including melanoma, prostate, breast, lung and other
cancers [111]. Cancer vaccines are biological preparations designed to stimulate immune
cells, mainly CD8+T cells, and direct them to recognize and kill specific types of cancer.
One approach to generate a cancer vaccine is to isolate tumor antigens from cancer cells
and immunize cancer patients directly with the main purpose of inducing greater immune
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responses against those specific antigens [112; 113]. Although many tumor antigens have
been reported for different cancers, not all of them can boost immune responses against
cancer cells. Therefore, many clinical cancer vaccine trials aim to select antigens that are
specifically recognized by CD8+T cells. Some examples of tumor antigens recognized by
CD8+T cells and have been demonstrated to boost anti-tumor responses following
vaccination are the melanoma-associated antigens: Melan-A/MART-1, NY-ESO-1 and
gp100 [114; 115; 116].

Cytokines have also been widely used as an active immunotherapy approach.
Cytokines are substances that are naturally produced by white blood cells and their main
role is to regulate immune responses. Some cytokines are known to increase the effector
functions of CD8+ T cells (i.e. IL-2), whereas other cytokines inhibit the activity of these T
cells (i.e. IL-10) [117]. Cytokines such as IL-2, IFN-α and GM-CSF have been frequently
used in the clinic [118]. GM-CSF and IL-2 have proven to be effective adjuvants to boost
the activity of cancer vaccines by either improving antigen presentation of tumor antigens
or by supporting the effector function of vaccine-induced T-cell immune responses [118].
IFN-α has already been approved by the FDA to treat many cancers, including melanoma
[119].

1.9 Dendritic Cell cancer vaccines

The generation of effective cancer vaccines depends not only on the discovery of
target antigens but also on strategies to deliver those antigens to elicit tumor-specific T cell
immune response. To elicit potent T-cell mediated immune responses against cancer,
several different cancer vaccines have now been designed and tested clinically to treat
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different types of cancers, including metastatic melanoma and lymphomas. These have
included immunizing patients with defined tumor-associated antigens (i.e. single peptides
or whole tumor proteins), naked plasmid DNA, attenuated viral vectors, and dendritic cells
(DCs) [120; 121]. Although early studies demonstrated that the use of each vaccine as
single therapy regimen induced low objective clinical responses, more recent studies have
shown that cancer vaccines are significantly more effective when used in combination with
adoptive cell transfer of tumor-specific T cells [36].
Of all the different vaccine formulations tested clinically, vaccines that utilize DCs
have demonstrated the best combination of safety and efficacy [43]. The main goal of DCbased cancer vaccines is to boost T cell-mediated antitumor immunity by introducing
dendritic cells loaded with specific tumor-associated antigens to patients. Different
methods to develop DC cancer vaccines have been used in both animal models and clinical
trials. One method is the ex-vivo generation of antigen-loaded DCs. This method involves
(1) the isolation of dendritic cells or precursors from the peripheral blood of cancer
patients, (2) the ex-vivo DC culture and loading with a specific antigen obtained from the
patient‟s own tumor and (3) the re-infusion of the antigen-loaded dendritic cells back into
the patients to boost T cell-mediated anti-tumor immune responses [35]. The use of these
ex-vivo generated DC cancer vaccines has generated effective anti-tumor responses in
different studies. For example, clinical studies have demonstrated that vaccination with
DCs pulsed with a melanoma antigen results in long term tumor regressions in patients
with late stage metastatic melanoma as compared to other vaccine approaches (i.e viral
vectors, plasmid DNA) [44; 122]. Also, our group has previously reported that giving a
combination of tumor antigen-specific CD8+ T-cells and DCs pulsed with a tumor peptide
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results in significant anti-tumor responses in a melanoma animal model [36]. Another
method to deliver antigens for the generation of DC cancer vaccines is the in vivo DC
targeting using antibodies against specific DC surface receptors, such as DEC205 [123;
124; 125; 126]. One advantage of this method is that is does not require the ex-vivo
generation of DCs, which can be an expensive process. Although clinical trials need to be
performed to demonstrate the effectiveness of the in vivo DC targeting method, preclinical
studies in mice demonstrate that such strategies promote substantial augmentation of
antigen-specific T cell immunity.

Understanding the biology of DCs is critical for the generation of effective DC
cancer vaccines. DCs have a number of important advantages over other vaccines. For
example, one advantage is that they have the ability to take up antigens from different
tissues, such as the skin, and process them for subsequent presentation to T cells. Another
advantage is that DCs express high levels of antigen presenting molecules (MHC
molecules) and co-stimulatory receptors (i.e. CD80, CD86) and secrete large amounts of
cytokines (i.e. IL-12) which are important for T cell activation, proliferation and
differentiation [35; 38; 127]. But perhaps the most important advantage is that they can
induce both therapeutic and protective anti-tumor immunity. Thus, DCs possess a number
of important attributes that make them highly suitable as vaccines for generating antitumor
immunity.

Although DC vaccine approaches have shown much promise, clinical responses
remain relatively rare. Recently, the FDA has approved the use of PAP-GM-CSF fusion
protein (Provenge) developed by Dendreon as the first therapeutic cancer vaccine for the
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treatment of prostate cancer [128; 129]. The approval of Provenge not only demonstrates
that efficacy of DC-based cancer vaccines in treating advance prostate cancer but it has
also opened the doors for the development of vaccines for other types of cancer, including
melanoma and breast [111].
Several limitations need to be overcome to increase the potency of current DC
vaccines. One limitation is that the presentation of peptides (i.e. tumor- associated
peptides) by DCs is limited due to rapid internalization of peptide/MHC class I complexes
into acidic intracellular compartments (i.e. lysosomes) for degradation [88; 130; 131]. This
rapid internalization process is regulated by the MHC class I cytoplasmic tail and limits the
cell surface half lives of peptide/MHC class I complexes for recognition by CD8+ T cells.
To overcome this limitation, we generated a modified DC vaccine with enhanced antigen
presentation capacity by introducing specific mutations into the MHC class I cytoplasmic
tail. One of the MHC class I modified DC vaccines demonstrated substantially increased
anti-tumor T cell responses in vivo as compared with a DC vaccine expressing the wild
type MHC class I variant [132]. These studies provide a strong rationale and method of
improving DC-based therapeutic vaccines for use in cancer therapy.
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1.10 Long term goal, objectives and hypothesis of the present work

The long term goal of this dissertation is to better understand the regulation of
MHC class I antigen presentation in DCs so that we can identify key target proteins that are
involved in MHC class I trafficking and antigen presentation at the molecular level. The
identification of these molecules may lead to new insights that will provide rationale for
improved design of DC-based vaccines. The generation of such vaccines may be used to
manipulate T-cell immune responses in different clinical settings including autoimmunity,
chronic infectious diseases and cancer. In particular, the main objectives of this
dissertation are to evaluate the role of the MHC class I cytoplasmic tail in DC-induced Tcell immune responses and to understand the role of the cytoplasmic tail in trafficking, cell
surface half-lives, clustering and polarization of peptide/MHC-I complexes, which are
critical for the initiation of CD8+ T cell-mediated immune responses.
We hypothesized that exon 7 encoded by the MHC-I cytoplasmic tail may regulate
DC antigen presentation and modulate T-cell immune responses. For this purpose, we have
evaluated the stimulatory capacity of DCs expressing exon 7-deleted MHC-I molecules at
inducing CD8+ T cell immune responses in vivo and invitro. In addition, we have
evaluated the cell surface half-lives and clustering of exon 7-deleted MHC class I
molecules in human DCs.
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CHAPTER 2-RESULTS
2.1 Mouse DCs express similar levels of wild type and Δ7 variants of H-2Db

To test the capacity of DCs expressing exon 7-deleted MHC class I at inducing
CTL- mediated immune responses, we first developed a PCR-based site-directed
mutagenesis protocol to specifically remove exon 7 (encoding 13 amino acids of the
cytoplasmic tail, including the serine phosphorylation site) of the mouse H-2Db
cytoplasmic domain [86]. Following sequencing analysis, bicistronic lentiviral vectors
under the regulation of the Mouse Stem Cell Virus (MSCV) promoter were generated to
induce the expression of WT H-2Db or Δ7 H-2Db molecules in mouse bone-marrow
derived DCs (BM-DCs) from DBA/2 mice (haplotype H-2d). Green fluorescent protein
(GFP) was also expressed from a downstream internal ribosome entry site (IRES) (Figure
A). To confirm the expression levels of WT H-2Db or Δ7 H-2Db molecules in DCs, we
stained surface H2-Db molecules using a fluorescently labeled H2-Db monoclonal antibody
and performed flow cytometry analysis at 72 h after transduction. The flow cytometry
analysis showed that DC transduction efficiencies range from ~15 to 30% using a MOI of
10. In addition, such analysis demonstrated that transduced BM-DCs express comparable
levels of WT H-2Db and Δ7 H-2Db molecules at the cell surface (Figure B). These data
indicated that peptide binding and trafficking of newly synthesized H-2Db molecules from
the endoplasmic reticulum to the plasma membrane was not affected by the mutations
generated in the cytoplasmic tail of H-2Db.
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Figure 3. Expression of WT and delta 7 variants of H2Db in mouse bone marrow
derived DCs following transduction. (A) Bicistronic lentiviral vectors encoding either
WT-H2Db, Δ7-H2Db or GFP molecules driven off by the Mouse Stem Cell Virus (MSCV)
promoter were used to transduce mouse bone marrow derived dendritic cells. Lenti vectors
also contain an IRES element to drive the expression of GFP. (B) Bone marrow-derived
DCs from DBA2 mice were transduced to express either wild-type (WT) H-2Db/GFP, exon
7-deleted (Δ7) H-2Db/GFP, or GFP alone. Following transduction, DCs were stained for
H2Db and the levels of H2Db and GFP molecules were analyzed by flow cytometry. U =
untransduced DCs, GFP = DCs expressing GFP alone, WT = DCs expressing wild type
H2Db/GFP and Δ7 = DCs expressing Δ7-H2Db/GFP. Reprinted from “Natural splice
variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell
responses and boosts anti-tumor immunity” Tania G. Rodriguez-Cruz, Shujuan Liu, Jahan
Khalili, Mayra Whittington, Minyin Zhang, Willem Overwijk and Gregory Lizee. PLos
ONE 2011 6(8):e22939.
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2.2 Δ7-Db DCs induce enhanced CD8+ T-cells effector functions in vitro.
The effector functions of melanoma specific CD8+ T-cells following stimulation
with transduced DCs were also evaluated. For this, transduced BM-DCs were pulsed with
titrated concentrations of human gp100 peptide and co-cultured with gp100-specific CD8+
T cells (Pmel-1 T cells) in vitro. Pmel-1 T cells were preferred in these studies because
they can recognize gp100 peptide in association with H2Db molecules [133]. Following 4h
of co-culture, flow cytometry analysis was performed to measure the surface expression of
CD107a (degranulation marker) and intracellular IFN-γ in Pmel-1 T cells.
The analysis demonstrated that BM-DCs expressing Δ7-Db and pulsed with 10nM
of hgp100 peptide stimulated a much higher proportion of Pmel-1 T-cells to produce
intracellular IFN-γ and express surface CD107a as compared to DCs expressing WT-Db
(71% vs. 20%) (Figure A). Similar results were also obtained at higher and lower peptide
concentrations (Figure B). Interestingly, we observed that DCs expressing delta 7 induced
strong Pmel-1 T-cell IFN-γ production at peptide amounts at least 10-fold lower than the
lower limit of IFN-γ detection for DC expressing WT-H2Db (Figure C), suggesting that the
binding properties of the TCR to its pMHC-I ligand may be modulated by modifications in
the cytoplasmic tail of MHC-I. In addition, naïve Pmel-1 T cells produced significantly
higher amounts of IFN-γ, IL-2, TNF-α, and GM-CSF following priming by DCs expressing
delta 7 H2Db as measured by a Luminex assay (Figure D). These data indicated that exon
7 deleted H2Db molecules retained their antigen presentation function in our DC-vaccine
settings. Also, these results suggested that deletion of exon 7 within the cytoplasmic tail of
MHC-I may increase the TCR affinity and avidity for gp-100/H-2Db complexes resulting
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in enhanced T-cell activation even at very low peptide concentrations. Based on these data,
we hypothesized that exon 7 deleted MHC class I molecules may induce stronger T-cell
anti-tumor responses in vivo and in clinical settings.
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Figure 4. Δ7/H-2Db DCs stimulate superior cytokine production and degranulation by
CD8+ T-cells. DCs expressing either WT-H2Db/GFP, Δ7-H2Db/GFP or GFP alone were
pulsed with different concentrations of hgp100 peptide, and co-cultured with gp100specific Pmel-1 CD8+ T cells for 4hours. Unpulsed DCs (0nM of peptide) were used as
controls. (A) A representative contour plot of intracellular IFN-γ production and CD107a
expression in Pmel CD8+ T cells following stimulation with transduced DCs. (B)
Percentage of intracellular CD107a in Pmel T cells following stimulation with transduced
DCs pulsed with titrated amounts of gp100. This data is a representative of one triplicate
experiment out of three. Data shows mean ± S.D. (C) Transduced DCs pulsed with titrated
amounts of hgp100 peptide were co-cultured with Pmel CD8+T cells for 18hrs. The levels
of IFN-γ production in supernatants were analyzed by ELISA. (D) IFN-γ, GM-CSF, IL-2
and TNF-α release by Pmel-1 T cells following 72hrs stimulation with hgp100 peptidepulsed (10 nM) DCs expressing either WT-H2Db/GFP, Δ7-H2Db/GFP or GFP alone, as
determined by Luminex. All results are representative of one from four replicate
experiments. Data shows mean ± S.D. p values were calculated using a Student t test
comparing the effects of delta 7 with WT-H2Db. * = p values <0.05. This research was
originally published in “Natural splice variant of MHC class I cytoplasmic tail enhances
dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity” Tania G.
Rodriguez-Cruz, Shujuan Liu, Jahan Khalili, Mayra Whittington, Minyin Zhang, Willem
Overwijk and Gregory Lizee. PLos ONE 2011 6(8):e22939.
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2.3 Δ7-Db DCs stimulate improved Pmel-1 T-cell priming in vitro and invivo.
Proliferation of tumor-specific T cells is critical for the sustentation of potent antitumor immune responses [32]. Therefore, we next tested the ability of DC vaccines
expressing exon 7-deleted H2Db molecules to induce the priming and proliferation of
antigen-specific CD8+ T-cells. For this, naïve Pmel-1 T cells were labeled with CFSE and
co-cultured for 4 days with hgp100-pulsed DCs expressing either WT-Db or Δ7-Db in vitro.
To assess the relative priming abilities of exon 7-deleted Db mutant, flow cytometry was
performed on day 2, 3, and 4 following DC stimulation. Flow cytometry analysis showed
that DCs expressing Δ7-Db molecules induced a significantly higher proportion of Pmel-1
T cells to undergo proliferation compared to DCs expressing WT-Db molecules under all
conditions tested. We also observed that the difference was particularly dramatic at limiting
peptide concentrations, with Δ7-DCs clearly outperforming the WT-DCs at 1 nM and
0.1nM peptide (Figure A). In particular, the most striking difference was observed at 96 hr
using 0.1nM of gp100 peptide. In this condition, Δ7-DCs improved the proliferation of
Pmel-1 T cells more than 10 fold as compared to WT-DCs. These results suggested that
deletion of exon 7 within the cytoplasmic tail of MHC-I may increase the antigen
presentation and priming capacity of DCs as well as the affinity and avidity of the TCR for
pMHC-I leading to a more sustained T-cell activation signaling.
Based on the results above, we then compared the capacity between WT and Δ7 DC
vaccines at inducing CD8+T-cell priming in vivo. For this, we co-injected naïve Pmel T
cells along with peptide-pulsed DCs expressing WT-Db or Δ7 Db into the tail-vein of Thy
1.2+ C57BL/6 recipient mice and analyzed T-cell proliferation. The percentage of Pmel-1
T cells in peripheral blood was analyzed by flow cytometry over time. Similar to the in
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vitro results, DCs vaccines expressing Δ7 Db molecules stimulated significantly better
Pmel-1 T-cell priming than DC vaccines expressing WT Db molecules (16% vs. 4% of total
CD8+ T cells at the peak of the response), Figure C. However, we also observed that T
cells from WT and Δ7 groups ceased proliferation by day 9 after injection. This may have
resulted due to large amounts of T-cell death since previous studies have demonstrated that
the majority of T-cells have short-half lives after priming. This result suggested that T-cell
priming and proliferation may be sustained by increasing DC vaccine doses [36]
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Figure 5. In vitro and invivo priming of CD8+ T cells following stimulation with
transduced DCs. (A) WT-H2Db/GFP, Δ7-H2Db/GFP or GFP DCs were pulsed with
titrated concentrations of hgp100 (25-33) peptide, and used to activate CFSE-labeled, naïve
Pmel-1 CD8+ T cells invitro. Proliferation of gated Pmel T cells was analyzed at 48 hours,
72 hours, and 96 hours of co-culture by flow cytometry based on CFSE dilution. Numbers
on histograms indicates the percentage of divided Pmel T cells following priming with DCs
expressing WT-H2Db (blue) or Δ7-H2Db (black). (B) Normalized data was plotted to
analyze statistical differences between WT and Δ7 DCs by using a student Ttest. * =
p<0.05, ** = p<0.01. Data was normalized to control samples (unpulsed DCs). GFP control
sample was referred as 1. Error bars represent SEM from three individual samples. (C)
Transduced DCs were pulsed with 300nM of hgp100 peptide, and adoptively transferred
along with Pmel-1 CD8+ T cells into C57BL/6 mice. DC-induced T-cell expansion in vivo
was analyzed by measuring the percentage of Thy1.1+ Pmel-1 T cells in peripheral blood at
days 3, 6, 9 and 14 following adoptive transfer. U, untransduced DCs. Error bars represent
SEM of three mice per group. This result is a representative of three independent
experiments. This data was originally published in “Natural splice variant of MHC class I
cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts antitumor immunity” Tania G. Rodriguez-Cruz, Shujuan Liu, Jahan Khalili, Mayra
Whittington, Minyin Zhang, Willem Overwijk and Gregory Lizee. PLos ONE 2011
6(8):e22939.
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2.4 Δ7-2Db DC vaccines induce improved T-cell anti-tumor responses in vivo
Because it has been shown that exon 7-deleted MHC class I molecules induced
enhanced anti-viral T-cell responses and that Δ7 H-2Db DCs lead to improved Pmel T-cell
proliferation [80] [and data presented above], we sought to determine whether DC vaccines
expressing Δ7 H-2Db could lead to better T cell-mediated anti-tumor responses. To test
this, we used an adoptive Pmel-1 T-cell transfer model in combination with DC vaccines to
treat gp100-expressing B16 melanoma tumors as described previously [36]. Mice were
first inoculated with B16 melanoma subcutaneously before given i.v. co-injection of Pmel1 T cells and gp100-pulsed DCs expressing WT or Δ7 H2Db molecules. Tumor size, levels
of Pmel-1 T cells in the blood and survival levels were then analyzed over time following
treatment.
We observed that the tumor size at day 23 post-treatment was significantly smaller
in mice treated with a Δ7-Db DC vaccine compared to mice treated with a WT-Db DC
vaccine (p = 0.04 at day 23) (Figure A). Also, the percentage of peripheral blood Pmel-1 T
cells was greater in tumor bearing mice treated with Δ7 DC vaccines at days 7 and 21
(Figure B). In addition Δ7 DC vaccines along with Pmel-1 T cells also resulted in a
significant survival benefit (mean survival 31d vs 20 d, p = 0.0004) compared to mice
administered with WT DC vaccines and Pmel-1 T cells (Figure C).
Collectively, these results indicated that Δ7 MHC class I molecules could provide a
substantial advantage over WT MHC class I molecules for stimulating T-cell mediated
anti-tumor responses in a DC-based cancer vaccine setting.
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Figure 6: CD8+ T-cell anti-tumor responses following stimulation with transduced
DCs. Transduced DCs pulsed with 300nM of hgp100 peptide were co-injected along with
Pmel CD8+ T cells into tumor (B16 melanoma) bearing mice, followed by 3 days of
intravenous IL-2. (A) B16 tumor size at different time points, following treatment with
transduced DCs along with Pmel T cells. This data is a representative of one from three
replicate experiments. Error bars represent mean ± S.D. * = p <0.05. p values were
calculated using a student t test. (B) Flow cytometry analysis of the relative percentages of
Pmel-1 T-cells in the peripheral blood of treated animals at days 7 and 21 after treatment.
This data is a representative of one from three replicate experiments. Error bars represent
mean ± S.D. * = p <0.05. p values were calculated using a student t test. (C) Survival
analysis of treated mice as measured by the Kaplan Meier method. A Student T test was
used to analyze the statistical significance of the groups. p = 0.0004 (mean survival 31d vs
20 d). All data are representative of a minimum of 3 replicate experiments. N = 8 mice per
group. This data was originally published in “Natural splice variant of MHC class I
cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts antitumor immunity” Tania G. Rodriguez-Cruz, Shujuan Liu, Jahan Khalili, Mayra
Whittington, Minyin Zhang, Willem Overwijk and Gregory Lizee. PLos ONE 2011
6(8):e22939.
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2.5 Transduced human DCs express comparable levels of wild type and Δ7 isoforms
of HLA-A*0201
The mechanistic insights from the murine studies prompted us to next evaluate
whether the Δ7 isoform of HLA class I could similarly enhance human CTL responses.
First, lentiviral vectors encoding WT (WT-A2) or Δ7 (Δ7-A2) HLA-A2 molecules under
the control of the human ubiquitous PGK promoter were developed and used to induce the
expression of such HLA-A2 variants into primary human DCs (derived from CD34+HSC)
and the human KG-1 DC-like cell line, (Figure A). Following 5 days post-transduction,
surface levels of WT-A2 and Δ7-A2 were measured in both CD34+-derived DCs and KG-1
cells using a HLA-A2 fluorescently-labeled monoclonal antibody and by flow cytometry.
The flow cytometric analysis demonstrated that transduced human DCs expressed
comparable cell surface levels of WT-A2 or Δ7-A2 (Figure B). We also observed that those
DCs expressed comparable levels of CD86, CD80, MHC class II, CD11c, B7H-1, B7-DC
and CD70 (data not shown). This data suggested that deletion of exon 7 from the HLA-A2
cytoplasmic tail did not abrogate the molecule‟s transport from the endoplasmic reticulum
to the cell surface of human DCs.
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Figure 7: Expression of WT and Δ7 variants of HLA-A*0201 in human DCs. (A)
Lentiviral vectors used to transduce human DC-like KG-1 cells and human CD34-derived
DCs. The human phosphoglycerate kinase (hPGK) promoter was used to drive the
expression of WT and Δ7 isoforms of HLA-A*0201. Bottom, Predicted amino acid
sequences of the cytoplasmic domains of WT and Δ7 HLA-A*0201. Exon 7-encoding
amino acids are depicted as red, and bold font indicates reported phosphorylation sites. (B)
Human DC-like KG-1 cells and primary CD34+-derived DCs were transduced to express
comparable levels of surface HLA-A*0201, as determined by HLA-A2-specific mAb
staining and flow cytometry. WT-A2, grey and blue histograms; Δ7-A2, black and green
histograms. Light grey histograms represent untransduced DCs. Reprinted from“Natural
splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell
responses and boosts anti-tumor immunity” Tania G. Rodriguez-Cruz, Shujuan Liu, Jahan
Khalili, Mayra Whittington, Minyin Zhang, Willem Overwijk and Gregory Lizee. PLos
ONE 2011 6(8):e22939.
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2.6 Δ7-A2/DCs facilitated augmented inflammatory cytokine production by human
CTL.
We next evaluated the capacity of human DCs expressing Δ7-A2 to stimulate
human antigen-specific CD8+ T cells effector functions. For this purpose, human DCs
(KG-1 cells and CD34+-derived DCs) expressing either WT-A2 or Δ7-A2 were pulsed
with different concentrations of MART-1 (melanoma antigen recognized by T cells) 27L
peptide. Peptide pulsed-DCs were then used to stimulate MART-1 specific CD8+ T cells in
an 18h invitro co-culture system. The levels of different inflammatory cytokines produced
by the MART-1 specific T cells following stimulation were then analyzed in co-culture
supernatants using ELISA and Luminex.
Similar to the murine studies, we observed that both human primary DCs and KG-1
cells expressing Δ7-A2 molecules and pulsed with 10nM MART-1 peptide significantly
increased IFN-gamma production from MART-1 specific CD8+ T cells as compared to
peptide-pulsed DCs expressing WT-A2. MART-1 specific T cells alone or co-cultured with
untransduced DCs (No-A2) produced almost undetectable amounts of IFN-gamma as
expected (Figure A). The difference in IFN-gamma production from MART-1 specific T
cells was even more significant at lower peptide concentrations. We observed that MART1 specific T cells produced undetectable amounts of IFN-gamma when DCs expressing
WT-A2 were pulsed with 1nM of peptide. However, at the same peptide concentration,
DCs expressing Δ7-A2 were able to stimulate MART-1 specific T cells to produce more
than 4,000 pg/ml of IFN-gamma, Figure B. In addition, we also evaluated the capacity of
DCs expressing Δ7-A2 to stimulate influenza matrix protein 1 (FluM1)-specific CD8+ T
cells from the peripheral blood mononuclear cells (PBMC) of normal donors. Similar to the
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studies using MART-1 specific T cells, KG-1 cells expressing Δ7-A2 molecules induced
significantly enhanced FluM1-specific inflammatory cytokine and chemokine production
compared to KG-1 cells expressing WT-A2 molecules. The levels of IFN-γ, MIP-1α and
MIP-1β were 3 to 5-fold higher and the levels of IL-2, MCP-1, and TNF-α were typically
>10-fold higher than WT-A2 stimulated T-cell cultures as measured by Luminex. The
levels of VEGF produced by Flu specific T cells following stimulation with transduced
DCs were almost undetectable in our invitro system, Figure C.
The fact that DCs expressing Δ7-A2 stimulated enhanced T-cell effector function at
very low concentrations of peptide suggested that the affinity and avidity properties of the
TCR may be modulated by specific motifs in the MHC-I cytoplasmic tail. Based on these
results and previous studies that have demonstrated that the efficacy of CTLs cellular
responses is highly dependent upon their functional avidity, we hypothesized that Δ7-A2
molecules may increase the functional avidity of effector T cells to recognize tumor cells or
infected cells during the killing or efferent phase. We tested this hypothesis in the human
T-cell expansion experiments.
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Figure 8: CD8+ T-cell inflammatory cytokine secretion following stimulation with
transduced human DCs. (A) Transduced KG-1 cells and CD34+-derived DCs were pulsed
with the melanoma peptide, MART-1 (100 nM), and co-cultured with MART-1-specific
CD8+ T cells. Overnight culture supernatants were analyzed for IFNELISA. (B) Transduced KG-1 cells were pulsed with titrated concentrations of FluM1
peptide, and used to stimulate influenza-specific CD8+ T cells. IFN-γ secretion in response
to titrated amounts of FluM1 peptide was analyzed by ELISA. (C) Specific inflammatory
cytokine release in response to DC stimulation for 18h, as determined by Luminex. All
results are representative of a minimum of 3 replicate experiments. * = p values <0.05. P
values were calculated using a student T test analysis comparing the effects of delta 7 with
WT-H2Db. This data was originally published in “Natural splice variant of MHC class I
cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts antitumor immunity” Tania G. Rodriguez-Cruz, Shujuan Liu, Jahan Khalili, Mayra
Whittington, Minyin Zhang, Willem Overwijk and Gregory Lizee. PLos ONE 2011
6(8):e22939.
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2.7 Δ7-A2/DCs improved the expansion of antigen specific CD8+ T cells
Because one goal of DC vaccines is to stimulate the expansion of human antigenspecific T cells, we next went onto determine whether DC expressing Δ7-A2 molecules
increase the expansion of HLA-A*0201 restricted CD8+T cells compared to DCs
expressing WT-A2 in an invitro co-culture system. For this, we isolated CD8+ T cells from
normal donor PBMCs (Flu specific T cells were <1% of the CD8+ T cell compartment)
and co-culture them with Flu-pulsed KG-1 cells expressing either WT-A2 or Δ7-A2 for the
period of 9 days. Following co-culture, the expansion of Flu-specific CD8+ T cells was
measured by using a FITC-conjugated CD8+ specific antibody, an APC-conjugated Flu
specific tetramer and flow cytometry.
We found that FluM1 peptide-pulsed Δ7-A2 KG-1 cells facilitated superior
expansion of FluM1-specific CD8+ T-cells compared with WT-A2 KG-1 cells (2 fold
increased expansion) and that this effect was most remarkable at lower peptide
concentrations (Figure A). However, we did not observe significant differences in the MFI
of tetramer staining following T-cell expansion. These results led us to think that Δ7-A2
may not affect the affinity and avidity of the TCR following priming since previous studies
have shown that the intensity of tetramer staining correlates with the affinity and avidity of
TCRs. We also observed similar results for the expansion of CMV-specific T cells from
normal donor PBMC following a single round of in vitro stimulation with transduced KG-1
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cells (Figure B). As expected, antigen specific T cells co-culture with untransduced KG-1
cells showed a modest expansion.
To test whether Δ7-A2 molecules may affect the functional avidity of the primed
Flu specific T cells during the killing or efferent phase, T-cell intracellular IFN-γ and
expression of CD107a was measured by flow cytometry following a second round of
stimulation with peptide pulsed T2 cells. Although their distinct expansion indices, we
found that CD8+ T cells expanded by either Δ7-A2 or WT-A2-expressing DCs were
equally functional with regard to functional avidity, intracellular IFN-γ levels, and
degranulation capacity (Figure C). These results suggested that deletion of exon 7 within
the MHC-I cytoplasmic tail increases the expansion and effector function of CTLs through
mechanisms independent of affinity and functional avidity of antigen specific T cells. We
also attempted to evaluate the in vitro expansion of melanoma-specific CD8+ T cells using
a single round of DC stimulation but was found to be significantly less robust compared
with virus-specific T cell expansion.

59

Figure 9: Expansion of human antigen-specific CD8+ T cells following stimulation
with transduced KG-1 cells. KG-1 cells expressing WT-A2 or Δ7-A2 molecules were
pulsed with 100nM of the influenza peptide (FluM1). Cells were then used to stimulate the
expansion of influenza-specific CD8+ T cells isolated from normal donors PBMCs in vitro.
Following 8days stimulation, the expansion of influenza-specific CD8+ T cells was
determined by tetramer analysis and flow cytometry. Numbers on top of blue squares
represent the % of Flu specific CD8+ T cells (Figure A). The % of Flu specific CD8+ T
cells and mean fluorescence intensity (MFI) of the Flu tetramer were analyzed to measure
statistical differences between the WT and Δ7-A2 groups following stimulation (Figure B).
Transduced KG-1 cells were pulsed with Flu peptide and CMV peptide (pp65 peptide) and
used to stimulate both Flu and CMV specific CD8+ T cells in vitro. The total number of
virus-specific CD8+ T cells was then analyzed by the tryptan-blue method following
invitro co-culture with transduced KG-1 cells (Figure C). Following expansion, T cells
were then analyzed for effector function. For this, expanded T cells were co-cultured with
T2 cells pulsed with titrated amounts of Flu peptide. After 4h stimulation, intracellular
IFN-γ and surface CD107a was analyzed by flow cytometry (Figure D). All data are
representative of at least 4 replicate experiments. Error bars represent SEM. A student T
test was used to calculate p values and evaluate statistical differences between the WT-A2
and Δ7-A2 experimental groups. Reprinted from “Natural splice variant of MHC class I
cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts antitumor immunity” Tania G. Rodriguez-Cruz, Shujuan Liu, Jahan Khalili, Mayra
Whittington, Minyin Zhang, Willem Overwijk and Gregory Lizee. PLos ONE 2011
6(8):e22939
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2.8. Δ7-HLA-A*0201 isoforms show increased bio-availability of MHC-I/peptide
complexes for recognition by CD8+ T cells.
Because previous studies have demonstrated that the duration of peptide/MHC
complexes at the cell surface plays a critical role in the activation of T cells, we
hypothesized that Δ7 MHC-I splice variant may show prolonged cell surface half-lives on
APCs leading to improved T cell activation and cellular responses [21]. To test this
hypothesis, we compared the surface half-lives of peptide/MHC class I complexes (WT or
Δ7) over time by using a TCR-like monoclonal antibody that specifically recognizes
MART-1/HLA-A*0201 peptide complexes. Consistent with murine studies [80] Δ7A2/MART-1 peptide complexes demonstrated extended cell surface half-lives that were
approximately twice that of WT-A2/peptide complexes in KG-1 cells (~16 h vs. ~8 h) as
measured by flow cytometry (Figure A). Furthermore, confocal microscopy of transduced
KG-1 cells revealed similar steady-state plasma membrane distributions of WT and Δ7
HLA-A*0201 when cells were incubated at 4°C. However when KG-1 cells were
incubated at 37°C, Δ7-A2 molecules demonstrated substantially impaired lateral membrane
movement and polar „capping‟ compared with WT-A2.

Instead, Δ7-A2 molecules

remained relatively evenly dispersed at the plasma membrane (Figure B).
Moreover, MART-1-specific CD8+ T cells co-cultured with peptide-pulsed KG-1
cells expressing WT-A2-GFP fusion proteins induced very similar clustering of WT-A2GFP molecules that was invariably localized at the region of the DC/T-cell interface
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(Figure C). However, Δ7-A2-GFP fusion proteins, showed little or no such membrane
spatial clustering in response to CD8+ T-cell contact (Figure C). As expected, the increased
spatial distribution of membrane Δ7-A2/MART-1 complexes was also associated with an
increase in the mean number of MART-1-specific T cells capable of forming conjugates
with co-cultured Δ 7-A2 KG-1 cells on a per-APC basis following 2 h of co-culture (Figure
D). Furthermore, larger order clusters of DC-T cell conjugates were formed after 6 hours of
co-culture (Figure E) indicating that antigen presentation by Δ7-A2 molecules increases Tcell/DC interactions.
These data suggested that lateral movement and MHC-I clustering at the plasma
membrane may be modulated by specific motifs within the cytoplasmic tail of MHC class I
molecules and that such modulation may regulate T cell response outcomes. Also, these
data suggested that delta 7 MHC class I molecules may show distinct signaling casacades
that may affect antigen presentation, survival and cytokine production profiles of the APCs.
However, how the MHC-I cytoplasmic tail modulate MHC-I clustering and signaling and
how these parameters affect T cell activation at the molecular level need to be determined.
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Figure 10: Surface mobilization and bioavailability of surface peptide/MHC class I
complexes in KG-1 cells expressing WT-A2 or Δ7-A2 molecules. KG-1 cells expressing
WT- or Δ7-HLA-A*0201 were pulsed with the melanoma-associated peptide (MART-1,
20nM) for 1hr at room temperature. Cells were then collected at different time points (0, 6,
12 and 24 hrs) following cell culture at 37°C, and stained at 4°C with a fluorescentlylabeled TCR-like mAb that specifically recognizes HLA-A2/MART-1 complexes (Altor
Biosciences). Graph depicts the mean fluorescence intensity (MFI) of surface WTA2/MART-1 and Δ7-A2/MART-1 complexes on the cell surface of transduced KG-1 cells
at each time point as analyzed by flow cytometry (Figure A). Transduced KG-1 cells were
stained with a fluorescently-labeled HLA-A2-specific mAb (green) on ice to label surface
HLA-A2 molecules. Cells were then incubated for 30 min at 4°C or 37°C and plated onto
poly-L-lysine treated coverslips for confocal microscopy analysis (Figure B). KG-1 cells
expressing WT-A2-GFP or Δ7-A2-GFP fusion proteins were pulsed with MART-1 peptide
(100 nM) and co-incubated with MART-1-specific CD8+ T cells (Figure C to E). Cells
were then stained for CD3 (red), and analyzed by confocal microscopy. Arrows show
augmented cell surface distribution of Δ7-A2/GFP fusion proteins (Figure C). Figure D
shows quantification of the mean number of CD8+ T-cells in contact with one KG-1
expressing either variant of HLA-A2 (WT or Δ7). Figure E demonstrates typical higherorder of APC/T-cell clusters as analyzed by light microscopy following 6h of co-culture.
Reprinted from “Natural splice variant of MHC class I cytoplasmic tail enhances dendritic
cell-induced CD8+ T-cell responses and boosts anti-tumor immunity” Tania G. RodriguezCruz,et al. PLos ONE 2011 6(8):e22939
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CHAPTER 3

DISCUSSION AND FUTURE IRECTIONS

3.1 Summary
The major aims of this dissertation were to evaluate the function of the MHC class I
cytoplasmic tail in DC-induced CTL anti-tumor and anti-viral responses, and in the
regulation of surface internalization and polarization. We have addressed these aims by
using both a melanoma mouse tumor model and a human in vitro DC/T-cell co-culture
system. Specifically, we have demonstrated that DCs expressing exon 7-deleted MHC
class I isoforms (Δ7-Db), stimulated remarkably higher levels of CTL-cytokine production
and also increased the proliferation of melanoma-specific (Pmel-1) T cells compared with
DCs vaccines expressing wild type MHC-I in vitro. Additionally, we have demonstrated
that, in combination with adoptive transfer of melanoma specific T-cells, DC vaccines
expressing Δ7-Db isoforms stimulated enhanced anti-tumor responses against established
B16 melanoma leading to extension of mouse survival. Moreover, we showed that human
DCs expressing Δ7-HLA-A*0201 molecules showed similarly augmented CTL stimulatory
ability as compared to DCs expressing WT-HLA-A*0201 molecules. Finally, we have
demonstrated that Δ7 MHC-I isoforms show impaired lateral membrane polarization and
extended cell surface half-lives within the DC/T-cell interface, leading to increased spatial
availability of MHC-I/peptide complexes for recognition by CD8+ T cells. Collectively,
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this work demonstrates that the MHC class I cytoplasmic tail plays a key role in the
generation of both mouse and human anti-tumor CTL responses.

3.2 MHC class I cytoplasmic tail splice isoform occur naturally in several species
The cytoplasmic tail of MHC-I shows an extraordinary high level of conservation
of certain amino acids including Tyrosine 320 in exon 6, and Serine-335 in exon 7 [80; 86].
Interestingly, these amino acids have been described to be the potential phosphorylation
sites of MHC class I [80; 87]. Several studies have reported different natural alternate
splice isoforms of MHC class I heavy chains and that the generation of most of these
isoforms involves the deletion of specific exons leading to truncated, elongated or soluble
MHC class I molecules [84; 85; 134]. Of interest, previous studies have reported that exon
7 splicing isoforms of MHC class I occur naturally in mice, cows, and chickens resulting in
a shorter cytoplasmic tail lacking the highly conserved Serine 335 phosphorylation site [84;
85; 86; 135]. One possible reason why alternative splicing occurs around exon 7 may be
because it is composed of less than 50 base pairs as demonstrated by previous studies,
which indicated that the length of internal exons plays a critical role in splice site selection
[136]. However, how these splice variants isoforms of MHC-I affect immune responses is
not well understood. Sequence analysis of more than 10,000 human expressed sequence
tags for HLA-A, -B, and –C have suggested that exon 7-deleted splice variants of classical
HLA alleles may not exist. Nevertheless, exon 7-deleted isoform of HLA-A*0201 showed
a significantly enhanced capacity to stimulate human CD8+ T cells, suggesting that a
potential loss of exon 7 splicing in humans during evolution may have had functional
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implications for adaptive immunity, potentially providing protection from CTL-mediated
autoimmunity or excessive inflammatory responses.

3.3 The role of the MHC-I cytoplasmic tail in the generation of T-cell responses
Because the presentation of peptides bound to MHC class I molecules is essential
for the activation of CD8+ T cells, we examined whether the cytoplasmic tail of MHC class
I molecules plays a functional role in the activation of both mouse and human CTL
responses. We first hypothesized that exon 7 encoded by the cytoplasmic tail of MHC-I
could regulate T-cell priming and effector function. To test this hypothesis, we generated
DCs expressing either wild type or exon 7-deleted mutants of both H-2Db and HLA-A2
and evaluated their stimulatory capacity to induce priming and effector function of antigenspecific T cells in vitro and invivo. We found that exon 7 of MHC class I is completely
unnecessary for the transport to the cell surface and as well as for the ability of MHC class
I to acquire peptides since these molecules were able to be to recognized by cognate CD8+
T cells. Interestingly, we found that exon 7-deleted MHC class I molecules significantly
induced superior T-cell immune responses as compared to native MHC-I in both murine
and human systems. Our findings are consistent with previous studies supporting the idea
that the MHC class I cytoplasmic tail contains motifs that can regulate T-cell activation
resulting in increased or decreased CTL immune responses [80; 88]. For example, one
study demonstrated that MHC class I molecules containing a point mutation in Tyr 320
(ΔY MHC-I) encoded by exon 6 of the cytoplasmic tail induced suboptimal CTL responses
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after viral challenge in vivo [80]. The same study also demonstrated that MHC-I molecules
lacking exon 7, in contrast to ΔY MHC-I molecules, induced superior CTL responses after
viral challenge [80]. Moreover, another study showed that HLA-A2 molecules lacking the
entire cytoplasmic tail demonstrated diminished recognition by EBV-specific T cells in
vitro [137]. However, our recent preliminary data indicated that H-2Db molecules lacking
the entire cytoplasmic tail induced T-cell proliferation similarly to native molecules in vivo
(Figure 13). Taken together these results suggested that the MHC class I cytoplasmic tail
can regulate T cell immune responses. The potential mechanisms by which MHC-I
cytoplasmic tail may regulate such immune responses are discussed below.

3.4 Role of MHC-I cytoplasmic tail in internalization and endocytosis
This and previous studies have clearly demonstrated that MHC-I molecules lacking
exon 7 induced superior CTL responses in vitro and in vivo [80] However, the potential
mechanisms of action that may contribute to such effect are poorly understood. Because it
has been demonstrated that internalization can affect the duration of antigen presentation
by MHC-I molecules, we first hypothesized that exon 7 of MHC-I molecules may regulate
internalization and that such regulation may lead to different T cell response outcomes
[130]. We found that Δ7 HLA-A2 isoforms show delayed internalization rates as compared
to WT-HLA-A2, suggesting that peptide/Δ7 HLA-A2 complexes are more stable at the cell
surface than peptide/WT-HLA-A2 complexes. These results were consistent with previous
studies demonstrating that specific mutations in the cytoplasmic tail of mouse MHC-I
alleles can impair MHC-I internalization and endocytosis [59; 60; 80; 88; 138]. The results
presented in this study suggested that internalization of MHC class I molecules can be
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modulated by exon 7 of the MHC class I cytoplasmic tail. However, how exon 7 of the
MHC-I cytoplasmic tail regulates internalization and trafficking of MHC-I molecules is not
very well understood at the molecular level.
Since Δ7 MHC-I lacks two highly conserved serine residues and one being the
phosphorylation site of MHC-I (Ser 335), it could be possible that serine phosphorylation
in exon 7 may initiate a signal cascade that promotes MHC-I internalization [87]. However,
how phosphorylation of MHC-I affect internalization at the molecular level has yet to be
elucidated. Previous studies have reported that MHC-I molecules can undergo
phosphorylation at the cell surface and in endosomal compartments [139]. Studies on
cytoplasmic tail mutants of MHC class I molecules have suggested that phosphorylation of
the cytoplasmic tail may play an important role in antigen presentation and trafficking of
MHC-I molecules. For example, independent studies have demonstrated that mutations in
the highly conserved tyrosine encoded by exon 6 of the MHC-I cytoplasmic tail impairs
MHC-I trafficking into endosomal compartments and abrogated the ability of DCs to crosspresent antigens [60; 80]. In addition, it has been suggested that phosphorylation of MHC-I
molecules may tag MHC-I to undergo endocytic trafficking since inhibition of MHC-I
phosphorylation by primaquine resulted in impaired recycling [139]. Moreover, it has been
suggested that the cytoplasmic tail of MHC-I contains endocytic motifs that may mediate
internalization possibly through interactions with different adaptor proteins, such as AP-2,
ARF-6, RhoA and Rab family members which are known to regulate internalization and
trafficking of different cell surface receptors by interacting with cytoskeletal components
[54; 65; 70]. Therefore, it is possible that serine phosphorylation in exon 7 of the MHC-I
may lead to the recruitment of AP-2 and/or ARF6 for example, and that such interactions
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may allow the recruitment of other molecules perhaps clathrin, Rab proteins or different
components of the cytoskeleton leading to rapid internalization and degradation [62; 71;
130; 138; 139]. It would be interesting to perform co-immunoprecipitation as well as
mutagenesis experiments to elucidate whether AP-2, ARF-6 and Rab proteins can bind to
exon 7 of the MHC-I cytoplasmic tail. These experiments may help to elucidate the
molecular mechanisms leading to MHC-I internalization and provide a better
understanding on how antigen presentation can be regulated.
However, we also found that although the reduced MHC-I DC surface
internalization contributed to enhanced CTL immune responses, much of the increased
stimulatory capacity by Δ7 was observed at early time points of DC-T cell interactions (1
to 3 hours), when WT MHC-I molecules had yet to undergo significant internalization.
These results suggested that other cellular mechanisms such as cytoskeleton-induced
polarization and clustering of MHC class I molecules towards the immune synapse may
also contribute to the greater stimulatory capacity of Δ7 MHC class I molecules. In fact, it
has been demonstrated that MHC-I clustering can affect the sensitivity ofT-cell recognition
and that the DC cytoskeleton is required for the polarization and the formation of a
functional immunological synapse but the molecular events are yet to be elucidated [140]
[141; 142].

3.5 Role of the cytoplasmic tail in MHC-I clustering

To evaluate whether the cytoplasmic tail plays a role in cytoskeleton-induced
polarization and clustering, we compared cell surface clustering of WT versus Δ7 MHC
class I molecules in DCs following TCR ligation by confocal microscopy studies. We
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found that recognition of peptides at the cell surface of APCs by cognate CD8+ T cells lead
to rapid „super clustering‟ of WT MHC-I molecules at the site of T-cell contact. This result
supported previous studies and our data suggesting that rapid internalization of MHC-I
molecules is initiated following „super clustering‟ at the cell surface [141; 143]. We
observed that this „super clustering‟ of WT MHC class I molecules greatly limited the bioavailability of MHC-I/peptide complexes for recognition by CD8+ T cells. However, unlike
WT MHC class I molecules, Δ7 MHC-I molecules showed significantly impaired „super
clustering‟ at the site of T-cell contact, leading to increased MHC-I/peptide complex bioavailability and enabling APCs to stimulate more CD8+ T cells on a per-cell basis.
These results are consistent with previous studies demonstrating that MHC class I
clustering at the cell surface of APCs modulates sensitivity of T cell recognition [141]. In
addition, these results revealed that exon 7 in the cytoplasmic tail of MHC-I may regulate
MHC-I clustering at the immunological synpase. However, how the cytoplasmic tail of
MHC-I influences clustering at the molecular level is not well understood. Biophysical
studies on lateral mobility and diffusibility have suggested that MHC-I molecules must
cross the barriers imposed by the membrane lipid raft domains in the sub-membrane
cytoskeleton in order to accumulate in the immunological synapse [141; 144; 145]. Studies
by Damjanovich demonstrated that MHC class I clustering at the immune synapse involves
dynamic homoassociations of MHC class I molecules as well as dynamic
heteroassociations between MHC-I molecules and other proteins, including adhesion
molecules and co-stimulartory molecules [146; 147]. Moreover, it has been demonstrated
that the diffusion of MHC-I molecules in the plasma membrane is influenced by structural
features of the MHC-I molecule and by the underlying cytoskeleton [148]. For example,
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fluorescence photobleaching and recovery experiments on truncation mutants of MHC-I
have demonstrated that the cytoplasmic tail restricts MHC-I mobility on the membrane by
interacting with the cytoskeleton, which restricts the molecule‟s lateral diffusion in the
membrane [148]. For example, studies by Capps have demonstrated that H-2Ld mutant
having a cytoplasmic tail of seven amino acids was as restricted in its lateral mobility as the
WT molecule with a full length of 31 amino acids. In contrast, H-2Ld mutants having a
cytoplasmic tail of 4 amino acids or no cytoplasmic tail had a higher mobile fraction and a
longer barrier-free path that did the WT molecules [145; 149; 150]. These studies
suggested that the length and charge of the MHC class I cytoplasmic tail affects lateral
diffusion. Consistent with those studies, we found that HLA-A2 molecules with full length
cytoplasmic tail showed T-cell induced restricted lateral mobility in human DCs. By
contrast, exon 7-deleted HLA-A2 molecules showed impaired clustering suggesting that
these variant of HLA-A2 may have a longer barrier-free path. These results indicated that
exon 7 of the MHC-I cytoplasmic tail may contain specific motifs that can regulate MHC-I
clustering and diffusion.
Exon 7 encoded by the MHC cytoplasmic tail contains two serine phosphorylation
sites and it has been suggested that phosphorylation of the cytoplasmic tail of MHC class I
has a role in the interactions between class I MHC molecules and cytoskeletal structures
[87]. Moreover, it has been suggested that the cytoplasmic tail of MHC class I molecules
could bind proteins of the membrane barrier through electrostatic or stereospecific
interactions, suggesting that specific post-translational modifications in the MHC-I
cytoplasmic tail may affect MHC-I cell surface clustering and distribution [150] . Based on
our data, it is possible that serine phosphorylation in exon 7 may initiate clustering of
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MHC-I at the APC/T cell contact area by perhaps leading the recruitment of cytoskeletal
components that mediate receptor mobility at the cell surface. In fact, it has been
demonstrated that ligation with antibodies induces phosphorylation of the MHC-I
cytoplasmic tail leading to rapid MHC-I clustering, which then promotes the activation of
signaling molecules involved perhaps in internalization and degradation [139]. Delta 7
molecules may have showed impaired clustering perhaps due to differences in sequence
charges, length of the molecule and steric forces that may affect interactions with the
cytoskeleton and other membrane proteins [150]. These results suggested that serine
phosphorylation of MHC-I may regulate T cell responses by inducing MHC clustering.
However, the factors that may initiate MHC-I phosphorylation (i.e. TLR signals, kinases)
and the potential cytoskeletal components that interact with the cytoplasmic tail of MHC-I
are yet to be identified. The identification of such elements (kinases and cytoskeletal
components) may provide insights on how MHC-I clustering is regulated at the molecular
level. The understanding of MHC-I clustering at the molecular levels may be important for
the generation of therapies that can modulate T cell responses in different clinical settings.
A proposed model for the regulation of MHC-I clustering is described in Figure 12.
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Figure 12: Proposed model for the regulation of MHC-I clustering. Surface MHC-I
molecules found in lipid raft domains (small yellow circles) may become phosphorylated in
exon 7 resulting in the recruitment of cytoskeletal components (i.e. actin filaments) to the
cytoplasmic tail of MHC-I. Such interactions may results in plasma membrane mobility
(arrows show mobility direction) and polarization of MHC-I towards specific membrane
domains through the cytoskeleton. Once „super clustering‟ of MHC-I (big yellow circle)
occurs, it delivers a signal for MHC-I/peptide complex internalization and degradation.
Exon 7-deleted MHC-I molecules do not show „super clustering‟ and therefore they do not
undergo rapid internalization and degradation.
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3.6 The role of the MHC class I cytoplasmic tail in signal transduction

Based on the results presented in this dissertation, we first hypothesized that
deletion of exon 7 in MHC-I molecules may have significantly enhanced T cell priming by
impairing MHC-I internalization, lateral movement and clustering and that such defects
resulted in significantly increased bioavailability of MHC-I/peptide complexes for cognate
CD8+ T cells.

However, more recent preliminary results from our laboratory have

suggested that this hypothesis may not fully explain how the cytoplasmic tail of MHC-I
influences T cell activation. Specifically, we found that MHC-I mutants lacking the entire
cytoplasmic tail showed similar internalization defects and cell surface distribution as Δ7
MHC-I molecules but, however, such Tail-less molecules did not affect the DC-induced Tcell proliferation invivo. Instead, DC expressing Tail-less molecules showed similar
stimulatory capacity as DCs expressing WT MHC class I molecules (Figure 13). Therefore,
increased bioavailability of MHC-I at the cell surface may not be the only explanation for
why Δ7 MHC-I molecules enhanced T cell priming. Nevertheless, these data suggested that
the cytoplasmic tail of MHC class I molecules contain domains that may differentially
regulate T cell responses perhaps by providing positive and negative signals to T cells or
even to the DCs. Based on these data, it is tempting to speculate that exon 6 contain motifs
that may play a role as a positive regulators of CTL immune responses whereas exon 7
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contain motifs that may play a role as negative regulators of CTL responses and that such
regulation by these domains could maintain homeostatic T cells responses. Because exon 6
contains a highly conserved tyrosine residue and exon 7 contains two highly conserved
serine residues, it is possible that phospshorylation of these residues may differentially
influence signaling perhaps in both T cells and APCs leading to different immune
outcomes (see below). We are currently generating cytoplasmic tail mutants lacking exon 6
in order to test whether this portion of the MHC-I cytoplasmic tail plays a positive
regulatory role in T-cell responses. If our hypothesis is correct then we would expect that
exon 6-deleted MHC-I molecules will not induce T cell responses while exon 7-deleted
MHC-I molecules will increase T cell responses as compared to WT MHC-I after
challenge.
One possible mechanism could be that specific motifs encoded by the cytoplasmic
tail of MHC class I may differentially regulate signal transduction pathways involved in
cell differentiation, survival and proliferation of both DCs and T cells. In fact, MHC class I
molecules have been involved in signal transduction in T cells, endothelial cells and
smooth muscle cells [151; 152; 153] For example, previous studies have demonstrated that
cross-linking of MHC class I on the surface of T cells activates the ZAP70 and p56
tyrosine kinases and induces δ-chain phosphorylation leading to an increase in intracellular
free calcium concentration, IL-2 production and proliferation, as well as an increase in the
expression of costimulatory receptors [154]. Moreover, it has been demonstrated that crosslinking HLA class I molecules in human endothelial cells (EC) resulted in signal
transduction pathways that stimulated both EC proliferation and survival. Specifically,
these studies reported that engagement of MHC class I molecules in EC induces tyrosine
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phosphorylation of Src family protein kinases and activation of focal adhesion kinase
(FAK). Moreover, they showed that MHC-I mediated activation of FAK triggers a prosurvival signaling cascade, resulting in the activation of PI3K/Akt-signaling pathway and
upregulation of anti-apoptotic proteins such as Bcl-2 and Bcl-xL [151; 153]([155; 156].
These studies suggested that Class I-mediated upregulation of anti-apoptotic proteins
renders EC resistance to complement mediated lysis. Thus, it is possible that engagement
of MHC class I molecules by the TCR may play an important role not only in T cell
activation but also in DC survival and function. However, the role of the MHC class I
cytoplasmic tail in signal transduction pathways in DCs is not well understood.
Previous studies have demonstrated that cytoplasmic tail of MHC class I molecules
is constitutively phosphorylated in vivo on a serine residue encoded in exon 7, suggesting
that such exon may be involved in signal transduction pathways [87]. However, other
studies have revealed that the cytoplasmic tail of class I molecules is not involved in T cell
activation since cross-linking truncated MHC class I molecules (no cytoplasmic tail)
induce IL-2 production similar to that induced by the native molecules, suggesting that the
cytoplasmic tail of class I MHC molecules is not involved in signaling [157]. However,
our results indicated that deletion of exon 7 leads to enhanced T-cell responses suggesting
that it may regulate signaling cascades. Interestingly, it has been demonstrated that crosslinking of MHC class I molecules leads to phosphorylation events which resulted in the
association of MHC class I molecules with other signaling receptors including insulin
receptor (IR) and GLUT-4, on the cell surface of DCs suggesting that association of MHCI with other receptors may propagate a signaling cascade leading to perhaps increased DC
activation, survival and antigen presentation [131; 158]. However, the role of the MHC
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class I cytoplasmic tail in the association of MHC-I with other receptors (i.e. IR) has not
been reported. It is possible that specific motifs encoded by the cytoplasmic tail of MHC-I
and their phosphorylation status may regulate interactions with other receptors leading to
cell survival through mechanisms that may involve steric forces. In fact, it has been
demonstrated that steric forces between the cytoplasmic tail of different receptors regulate
the formation of different heterodimers at the cell surface [146]. Based on this, it is
possible that MHC class I molecules associate with other signaling receptors at the cell
surface of DCs and that such associations may be interrupted following serine
phosphorylation in exon 7 of MHC-I leading to pro-survival signaling shutdown. This
could be tested by analyzing the expression levels of anti-apoptotic molecules including
Bcl-2 and Bcl-xL in DCs expressing either WT or Δ7 MHC class I molecules before and
after co-culture with T cells. Increasing the survival rates of DCs may be beneficial for the
generation of prolonged T cell immune responses. The proposed model describing a
potential role of conserved motifs in the cytoplasmic tail of MHC class I is shown in Figure
14.
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Figure 13. The cytoplasmic tail of MHC-I can influence T-cell priming. Naïve Thy1.1+
CD8+T cells from Pmel mice were co-injected along with gp100 pulsed DCs expressing
either WT (blue), Δ7 (black) or Tail-less (orange) variants of H-2Db into C57 mice. T cell
proliferation in peripheral blood over time was analyzed as readout for T cell priming.
Error bars represent SEM of three mice per group.
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Figure 14. Hypothetical model of the role of conserved motifs in the cytoplasmic tail
of MHC class I. The cytoplasmic tail of MHC class I molecules is composed mainly of
two exons. Exon 6 (red) encodes a highly conserved tyrosine at position 320 (blue). This
exon may function as a positive regulator of CTL responses following post-translational
moifications (i.e. phosphorylation). Exon 7 (black) encodes a highly conserved serine motif
at position 335 (blue). Based on this and other studies, we speculate that this exon may
negatively regulate CTL responses following phosphorylation. TM = transmembrane
domain.
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3.7 Does the cytoplasmic tail of MHC-I affect cross-dressing?
Recent studies have demonstrated that cross-dressing is another antigen
presentation mechanism by which DCs induce the activation of T cells. Cross-dressing
refers to the transfer of membrane peptide/MHC class I molecules from one DCs (donor
DC) to another DC (recipient DCs), which then presents the peptide to CD8+ T cells
without the need of any antigen processing [159] [160]. This antigen presentation
mechanism has been elegantly demonstrated by Wakim and Bevan to occur via cell-cell
contact or trogocytosis and not through the secretion of exosomes [159]. These studies also
showed that antigen presentation through cross-dressing of peptide/MHC-I complexes is
very inefficient for the activation of naïve T cells possibly due to the presentation of
vanishingly small number of peptide/MHC class I complexes. However, the mechanisms
that regulate trogocytosis are not understood. Because we observed more peptide/MHC
class I complexes at the cell surface of DCs expressing Δ7 MHC class I molecules as
compared to DCs expressing WT MHC-I, it is possible that the cytoplasmic tail of MHC-I
may regulate trogocytosis of peptide/MHC-I complexes from one DC to another DC,
which then results in T cell activation. In particular, we speculate that Δ7 MHC class I
molecules, lacking 13 amino acids including two potential serine phosphorylation sites,
may be transferred from one DC to another more efficiently than WT MHC-I molecules
maybe because such molecules are less heavy or/and contain the appropriate net charge
allowing more transfer. Such increment in trogocytosis of peptide/MHC-I complexes may
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allow DCs to present higher quantities of antigens to cognate T cells as well as to induce a
more sustained signaling cascade leading to survival, proliferation and differentiation in
both cross-dressed DCs and T cells. Also, it is possible that phoshorylation of MHC-I may
affect trogocytosis, however, this need to be determined. These ideas could be tested by
analyzing the transfer of WT and cytoplasmic tail mutants of MHC class I (i.e. Δ7) from
one DC to another DC. For example, we could introduce the expression of either WT or Δ7
HLA-A2 fused to GFP into donor DCs and then co-culture these donor DCs with HLA-A2
negative recipient DCs to allow trogocytosis. Then the cross-dressed DCs expressing WT
or Δ7 HLA-A2 could be analyzed for surface expression of transferred MHC-I and for their
capacity to stimulate T cells. In addition, the capacity of transferred MHC-I molecules to
stimulate signaling cascades could be also tested by analyzing the expression levels of prosurvival molecules in cross-dressed DCs as well as analyzing T cell signaling by measuring
the levels of phosphorylated ERK in T cells, for example. Understanding how crossdressing is regulated at the molecular level may provide new insights for the generation of
new DC vaccines.

3.8 Pharmacological implications
Although the cellular and molecular mechanisms that regulate internalization,
clustering and turnover of MHC-I/peptide complexes in DCs are mostly unknown,
understanding such mechanisms is an important first step for the development of efficient
therapies. In this study, we demonstrated that DCs induced to express Δ7 MHC-I enhanced
T-cell mediated anti-tumor responses and significantly prolonged mouse survival. These
findings suggested that similar strategies could increase the efficacy of human DC cancer
vaccines developed to induce anti-viral or anti-tumor specific CTL immune responses.
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However, we encountered two main limitations of using DCs vaccines engineered to
expressed different MHC class I isoforms over the course of this study. The first limitation
was the very often poor transduction efficiencies obtained following DCs infection with
lentiviral vectors encoding different MHC class I isoforms. The second limitation was that
CTL responses were restricted against one single MHC class I allele (H-2Db or HLAA*0201). Based on this, we speculated that it may be more effective to directly target exon
7-encoded determinants pharmacologically in order to counteract their negative effect on
CTL priming. Such an approach may be superior because it could simultaneously improve
antigen presentation by all endogenously-expressed HLA alleles.
Although the protein binding partners (i.e. kinases and phosphatases) of the MHC
class I cytoplasmic tail are still unidentified, exon 7 does encode a highly conserved serine
phosphorylation site (Ser-335) that may serve to regulate the trafficking and antigen
presentation capacity of MHC-I molecules. Additionally, exon 6 is composed of at least
two other possible motifs for protein post-translational changes. One motif is the highlyconserved putative phosphorylation site at Tyr-320, and the second motif is the highlyconserved ubiquitination site at Lys-316 [161]. If these post-translational modifications in
the cytoplasmic tail influence MHC-I function in vivo, then we speculate that inhibitors of
the kinases, phosphatases, or ubiquitin ligases that target the MHC-I tail may function as
highly immunomodulatory therapies. These studies will not only address how MHC class I
is regulated at the molecular level, but they might open a door toward the generation of
new pharmacological drugs that may serve to manipulate CTL priming responses at the
level of antigen presentation via the direct targeting of the MHC-I cytoplasmic tail.
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CHAPTER 4

EXPERIMENTAL PROCEDURES

4.1 Mice and B16 melanoma
DBA/2, C57BL/6 and Thy1.1+ Pmel-1 transgenic mice were maintained in a
pathogen-free facility at the MD Anderson Cancer Center. CD8+ T cells expressing a TCR
restricted to H-2Db molecules presenting the melanoma tumor antigen, gp100 (gp10025-33)
were isolated from the spleens of Thy1.1+ Pmel-1 transgenic mice. The majority of the
CD8+ T cells from these transgenic mice were VB13+ Thy1.1+ (>95%) as measured by
flow cytometry. All of the protocols conformed to MD Anderson Cancer Center guidelines
for the care and use of laboratory animals. The murine melanoma cell (B16) was obtained
from the National Cancer Institute tumor repository (Bethesda, MD) and maintained in
RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.03% Lglutamine, 100ug/ml streptomycin, 100ug/ml penicillin, and 50ug/ml gentamicin sulfate.
All cell culture reagents were obtained from Invitrogen.

4.2 Human cell lines
The human DC-like cell line, KG-1, was obtained from ATCC (CCL-246™) and
maintained in Iscove's Modified Dulbecco's Medium containing 20% Fetal Bovine Serum,
Glutamax, 100ug/ml Penicillin and 100ug/ml streptomycin. 293METR cells were a kind
gift from Brian Rabinovich (MD Anderson Cancer Center). These cells were maintained in
Dulbecco‟s Modified Eagle Medium supplemented with 10% Fetal Bovine Serum, HEPES,
Glutamax, Penicillin/Streptomycin and Normocin (all from Invitrogen). The MART-1
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specific T cell line, DMF5, was kindly provided by Laura A. Johnson from the NIH. These
MART-1 specific T cells were cultured in RPMI containing 10% FBS, HEPES, Glutamax,
Penicillin/Streptomycin. In addition, the human recombinant IL-2 (300 IU/ml) was added
every other day. Human recombinant IL-2 was obtained from ProLeukin (Novartis).

4.3 General cloning strategy for HLA-A2 and H-2Db molecules
We utilized the Gateway system (Invitrogen) to clone different HLA-A2 and H-2Db
variants into lentiviral expression vectors. First, we designed gateway-adapted primers to
amplify HLA-A*0201 and H-2Db from pcDNA 3.1 HLA-A2 (NCBI) and pcDNA 3.1 H2Db (James Gibbs, NIAID), respectively. The primers were designed to insert highly
specific recombination sites (attB1 and attB2) at the 5‟ and 3‟ end of each molecule (see
cloning strategy and primer list below). We also added EcoR1 and Cla-I restriction sites at
the 5‟ and 3‟ end of the primers, respectively. The amplified PCR products flanked by
attB1 and attB2 sites were then purified and cloned into the gateway entry vector, pDONR
222. pDONR 222 was used because it contains recombination sites that specifically
recognize the attB1 and attB2 sites during BP recombination reactions. Following BR
reactions, the products were then used for bacterial transformations and DNA from
different clones was analyzed by sequencing. Validated clones were named pDONR222
HLA-A2 and pDONR222 H-2Db. pDONR 222 HLA-A2 and pDONR222 H-2Db entry
vectors were then used to modify the cytoplasmic tail of both mouse and human MHC
class I molecules. The different MHC class I variants were then transferred from the entry
vector to different gateway-adapted lentiviral expression vectors via LR reactions. The

91

gateway-adapted lentiviral expression vectors were used because they specifically
recognize the recombination sites located in pDONR 222.
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Figure 15: Cloning different MHC class I molecules into Gateway-adapted entry
vectors. (A) MHC class I molecules (orange) were amplified using primers containing the
recombination sites attp1 and attp2 (patterned arrows). The PCR products were then cloned
between the B1 and B2 sites of the gateway-adapted entry vector, pDONR 222 via BP
reactions. The resulting vector was selected by kanamicyn (KanR) resistance and used for
transferring the gene into gateway-adapted lentiviral expression vectors. (B)
Recombination of pDONR 222 MHC class I (left) into a lentivirus expression vector
containing a mammalian promoter (i.e. human PGK or MSCV promoter) was performed
using LR reactions.
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Figure 16: Cloning different MHC class I molecules into Gateway-adapted entry
vectors. (A) MHC class I molecules (orange) were amplified using primers containing the
recombination sites attp1 and attp2 (patterned arrows). The PCR products were then cloned
between the B1 and B2 sites of the gateway-adapted entry vector, pDONR 222 via BP
reactions. The resulting vector was selected by kanamicyn (KanR) resistance and used for
transferring the gene into gateway-adapted lentiviral expression vectors. (B)
Recombination of pDONR 222 MHC class I (left) into a lentivirus expression vector
containing a mammalian promoter (i.e. human PGK or MSCV promoter) was performed
using LR reactions.
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4.4 Generation of Δ7 MHC class I molecules
Mutagenesis in the cytoplasmic tail of MHC class I molecules was performed using
a PCR-based site directed mutagenesis (Stratagene). To generate Δ7 MHC class I
molecules, we performed site-directed mutagenesis PCR on pDONOR222 WT-A2 and
pDONOR222 H-2Db using mutagenic primers designed to specifically delete exon 7 in the
cytoplasmic tail of both H-2Db and HLA-A2 molecules (see primer design and primer
sequences below). For example, the forward primer (1) was designed to anneal several base
pairs located at the end of exon 6 and several base pairs from the start end of exon 8. A
second primer (2) was designed to be the reverse complement of the forward primer.
Sequences in exon 7 were not included in these primers to allow the deletion of exon 7
during the PCR. PCR products were analyzed by gel electrophoresis and used to transform
bacteria. DNA from different bacterial clones was purified and sent out for sequencing
analysis (MD Anderson, DNA core). Validation of clones was performed by using the
alignment program of the Vector NTI software (Invitrogen). Validated clones were then
transferred into a HIV-based lentivirus expression vector containing the human PGK
promoter via gateway recombination LR reactions (Gateway technology from Invitrogen).
The products of the LR reactions were then used for bacterial transformations to amplify
the expression vector followed by generation of lentiviral virions for transductions.
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Mutagenic primers for human and mouse MHC class I molecules :
1. HLA-A*0201
5‟ CTCTCAGGCTGCAGTGTGAATCGATG
3‟ CATCGATTCACACTGCAGCCTGAGAG
2. H-2Db
5‟ GCTCTGGCTCCAGCGTGAGACCCAGC
3‟ GCTGGGTCTCACGCTGGAGCCAGAGC

4.5 Generation of different HLA-A2/GFP fusion proteins
To generate different HLA-A2/GFP fusion proteins, the WT and Δ7 variants of
HLA-A*0201 generated in the section above were amplified by PCR. The primers used for
PCR were designed to contain unique EcoR1 and ClaI sites at the 5‟ end and 3‟ end,
respectively. The Cla-I site at the 3‟ end was used to substitute the stop codon of the
different HLA-A2 variants in order to allow the translation of the fusion protein. The PCR
products were then confirmed by gel electrophoresis and purified using a Qiagen PCR
purification kit (Invitrogen). The purified products were then cut using the EcoR1 and ClaI
restriction enzymes and transferred into pENTR1A/GFP (a kind gift from Brian
Rabinovich, MD Anderson) by ligations. We choose to use the pENTR1A/GFP vector for
generating the fusion proteins because it has been characterized to contain a death cassette
flanked by unique EcoR1 and ClaI sites at the 5‟ end and 3‟ end, respectively. Also because
it has a linker that allows the proper folding of the fusion protein, and the green fluorescent
protein (GFP), both being downstream of the death cassette. The different HLA-A2
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molecules (minus stop codon) were ligated between the EcoR1 and Cla I sites of the death
cassette. Following ligations, the different HLA-A2/GFP constructs were then used for
bacterial transformations and the extracted DNAs were confirmed by DNA sequencing
Validated plasmids were then cloned into a gateway-adapted lentivirus expression vector
containing the human PGK promoter by using highly specific recombination reactions
(Gateway system, Invitrogen). Primers used for PCR are listed below.
Primers:
5’ EcoR1---HLA-A2 (Fwd)
GAATTCGCCACCATGGCCGTCA
3’ ClaI----HLA-A2 (Rev)
ATCGATCACTTTACAAGCTGTG

4.6 Generation of lentiviral vectors
Lentiviruses were generated by transient transfection of 293METR cells using
Lipofectamine 2000 (Invitrogen). Briefly, 293METR cells were transfected with plasmids
encoding either WT-HLA-A2, Δ7-HLA-A2, WT-HLA-A2/GFP, Δ7-HLA-A2/GFP, WTH-2Db or Δ7-H-2Db (2.3μg each), along with the packaging plasmids, p∆R8.91 (4.7μg) and
CMV-pVSVG (2μg), using Lipofectamine 2000 (1.6μg/ml). p∆R8.91 encodes the
structural gag and pol, and the tat and rev, which regulate viral gene expression [162]. The
CMV-pVSVG encodes the VSV-G envelope protein, which enables viral entry into cells.
Viral supernatants were collected at 48 and 72 hrs following transient transfection and
filtered using a 0.45μm membrane (Millipore). Viral supernatants were then concentrated
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by ultracentrifugation at 25,000rmp for 2 hours. Viral pellets were re-suspended at a 400X
concentrate in X-vivo15 serum-free medium and stored at -80°C.
4.7 Titration of Lentiviruses
2.5 x104 293 METR cells were resuspended in 1 ml of DMEM medium, plated in
24-well plate and cultured overnight at 37°C. Media was then removed and 200μl of fresh
DMEM was added to the cells for virus titrations. Serial dilutions (3 fold) of lentiviral
vector stocks were then added to the cells along with 8 μg/ml of polybrene (Sigma), which
enhances viral entry efficiency. Cells were then collected to measure transgene expression
using specific antibodies and flow cytometry. An anti-HLA-A2 monoclonal antibody
conjugated to alexa 488 (Serotec) was used to measure titrations of lentivirus encoding
different HLA-A2 cytoplasmic tail isoforms. An anti-H2Db monoclonal antibody
conjugated to alexa 647 (BD Biosciences) was used to measure titrations of lentiviruses
encoding different H2-Db cytoplasmic tail isoforms. Viral vector titrations were calculated
as follows: Transducing units (TU) per ml = % transgene positive cells x 50,000 cells /
volume of viral vector used (in ml).

4.8 Generation of primary dendritic cells
Mouse: Bone marrow-derived murine DC progenitors were isolated from the tibia and
femur of DBA/2 mice. The bone marrow was triturated using an 18 gauge needle and
passed through a 70μm nylon mesh cell strainer (Becton Dickinson) to make single cell
suspension in PBS. Bone marrow cells were then counted using a hemacytometer and
resuspended in complete medium consisting of RPMI 1640 supplemented with 10% heatinactivated fetal bovine serum and GM-CSF (50ng/ml) at a starting concentration of 5×105

100

cells/ml. Cells were incubated at 37°C for 7 days to induce the differentiation of cells into
immature dendritic cells. To generate mature dendritic cells, cells were incubated for 2
additional days in the presence of LPS.
Human: CD34+ cells were purified from HLA-A*0201 negative donor stem cells (a kind
gift from Nina Shah, M.D. Anderson) using CD34+ selection beads (Miltenyi) following
the manufactures instructions. Enriched CD34+ cells were incubated at 37°C for 2 weeks in
complete media containing RPMI + 5% human AB serum, Flt3L (100ng/ml), TPO
(100ng/ml) and stem cell factor (100ng/ml). Cells were then washed and incubated at 37°C
in RPMI + 5% human AB serum. Human recombinant GM-CSF (100ng/ml) and IL-4
(100ng/ml) were also added to the media and cells were incubated for 6 additional days in
order to induce the differentiation of immature DCs. To mature DCs, a combination of
poly:IC (5ug/ml), IFN-α (100ng/ml) and CD40L (200ng/ml) were added to the culture for
2 additional days. All cytokines were obtained from BD Biosciences.

4.9 Transduction of dendritic cells using lentiviruses
BM-DCs were transduced on day 3 using lentiviral vectors encoding WT-DbIRES-GFP, Δ7-Db-IRES-GFP, or empty-IRES-GFP. Cells were transduced by spinfection
using a multiplicity of infection (MOI) of 5 in RPMI supplemented with GM-CSF
(50ng/ml), and polybrene (4g/ml). Transduced cells were then incubated for 7 additional
days at 37°C in complete media supplemented with GM-CSF. Cell viability and
transduction efficiencies were then analyzed by FacScan (BD Biosciences). The human
HLA-A*0201 negative KG-1 cells [163], and CD34+-derived DCs were transduced with
lentiviral vectors encoding either WT-HLA-A*0201, Δ7-HLA-A*0201, WT-HLA-
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A*0201/GFP fusion protein or the Δ7-HLA-A*0201/GFP fusion protein in XVivo-15
serum free media (Cambrex). A MOI of 5 was used to transduce human cells. Polybrene
was also added to transduction conditions. Cells were then incubated for 5 days in the
appropriate culture medium, and transduction efficiencies were measured by flow
cytometry. KG-1 cells expressing comparable levels of cell surface WT-A2 and Δ7-A2
were purified by cell sorting. To ensure that the same number and percentage of WT- and
7-MHC-I expressing cells were used for all functional experiments, we first normalized
transduced primary CD34+-derived DCs for HLA-A2 expression.

4.10 T-cell cytokine production: ELISA, Luminex and Intracellular staining
Mouse T-cell cytokines: Mouse BM-DCs expressing either WT or Δ7 variants of H-2Db
were pulsed with titrated concentrations of hgp100 (25-33) peptide, and co-cultured with
Pmel-1 T cells at a 1:10 ratio at 37°C for 18hrs. Culture supernatants were collected and Tcell cytokine production was measured by mouse ELISA (Endogen) and Luminex
(Millipore). The IFN-γ ELISA method was performed according to the manufacturers
instructions after a 1:10 dilution of the culture supernatants. Seven standard curve points
were used: 2,500, 1000, 400, 160, 64, 25.6, and 0pg/ml. The samples were added in
triplicates of 50ul to each well. The plates were developed using TMB substrate for 15
minutes and the reactions stopped by adding 100μl of Stop Solution to each well. The
plates were read in a 96-well ELISA microplate reader (Tecan Group Ltd) using Megallan
V.400 software with a 450nm filter. The standard curve was generated by plotting the
average absorbance obtained for each standard concentration on the Y axis versus the
corresponding IFN-γ concentration (pg/ml) on the X axis. This standard curve was then
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used to determine the amount of IFN-γ in an unknown sample. The concentration of IFN-γ
in each sample was determined by multiplying the interpolated value obtained from the
standard curve by the dilution factor. The Luminex method was performed similarly to the
ELISA method but according to the manufacture‟s instructions.
Human T-cell cytokines: Transduced KG-1 or CD34+-derived DCs were pulsed with
titrated amounts of MART-1 or FluM1 peptides and co-cultured with MART-1 or Fluspecific T cells at a 1:10 ratio for 18h at 37°C. IFN-γ production was measured in culture
supernatants collected 18hrs following stimulation of antigen-specific T cells by peptidepulsed dendritic cells expressing either WT/HLA-A2 or Δ7/HLA-A2 molecules using
human IFN-γ ELISA kit (Endogen) and Luminex. The human ELISA and Luminex
methods were performed as described above.
Intracellular cytokine staining: Antigen-specific T cells were co-cultured with
transduced DCs for 4h in the presence of GolgiStop (BD Biosciences), washed, fixed,
permeabilized, and stained using anti-mouse or anti-human IFN- conjugated to FITC (BD
Biosciences). Mouse T cells were also stained with a fluorescently labeled CD107a specific
antibody (BD Biosciences) to measure degranulation. Human antigen-specific T cells were
also stained with MART-1 or FluM1 tetramers (Baylor College of Medicine) and a
fluorescently labeled anti-human CD8 antibody (BD Biosciences). Antigen-specific
intracellular IFN- production by CD8+ T cells was then determined by flow cytometric
analysis.
4.11 CFSE labeling
1μM of CFSE (Invitrogen) was used for labeling T cells to track their proliferation.
CFSE has a fluorescence exiting/emission profile similar to FITC. The proliferating cells
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can dilute CFSE and generate proliferation curves following stimulation experiments. T
cells were first washed in PBS and resuspended in PBS containing CFSE. Labeling was
performed in room temperature for 5 minutes followed by three times of wash using culture
medium. Stimulation was next set up as described earlier and CFSE dilution was measured
by flow cytometry using the FL-1 channel.

4.12 T-cell proliferation
Mouse studies: Naïve T cells isolated from the spleen of Pmel-1 mice were labeled
with CFSE (Sigma) and co-cultured invitro with Db-transduced DCs that had been pulsed
with titrated amounts of hgp100 peptide (0.1, 1 and 10 nM) at 37°C for 48, 72 and 96
hours. Cells were collected and stained using a fluorescently labeled anti-Thy.1.1 antibody
(eBioscience) and anti-mouse CD8 antibody conjugated to alexa 647 to label Pmel-1
CD8+T cells. Proliferation of gated Thy.1.1 CD8+ Pmel T cells was assessed by flow
cytometry over time. At least 10,000 cells were analyzed in each sample.
Human studies: HLA-A2-positive PBMCs from normal donors were obtained from
Gulf Coast Blood Center (Houston, TX).

Transduced KG-1 cells were pulsed with

different amounts of peptides for 2hr at room temperature. The HLA-A*0201-restricted
peptides used in the experiments were MART-1 (26-35,27L: ELAGIGILTV), influenza
matrix 1 protein (58-66: GILGFVFTL), or CMVpp65 (495-503: NLVPMVATV). All
peptides were obtained from Beckman Coulter. Following peptide pulsing, DCs were
irradiated with 20,000 rads, and co-cultured with antigen-specific human T cells at a ratio
of 1:10 at 37°C for 8 days. Cells were then collected and analyzed by flow cytometry to
determine the number of tetramer positive cells in the CD8+ T-cell population. The
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function of the expanded antigen-specific T cells was analyzed by measuring intracellular
IFN- staining and CD107a in response to antigen presentation by T2 cells.

4.13 Adoptive T-cell transfer, DC vaccination and Tumor treatment
To induce tumor growth, 5×105 B16 melanoma cells were injected subcutaneously
into C57BL/6 mice (8-10 weeks old). On day 7 after tumor injection, tumor-bearing mice
were subjected to irradiation (350 rad). Following irradiation, 5×106 T-cells from Pmel-1
mice were mixed with 1×106 transduced DCs pulsed with 300 nM of hgp10025–33 peptide
and adoptively transferred into irradiated tumor bearing mice for tumor treatment. IL-2
(6×105 units twice daily) was injected intraperitoneally for 3 consecutive days to support Tcell proliferation. Tumor size was measured every day following treatment using calipers,
and the products of perpendicular diameters were recorded. On day 7 and 21 following DC
vaccination, the percentages of peripheral blood Thy1.1+ Pmel-1 cells were analyzed by
flow cytometry. Mice were sacrificed when tumors exceeded 15 mm in diameter or became
ulcerated or mice became moribund. All invivo experiments were carried out in a blinded,
randomized fashion and performed three times.

4.14 Internalization of cell surface HLA-A2 in human dendritic cells
KG-1 cells induced to express either WT or Δ7 variants of HLA-A2 were stained
on ice for 30 minutes by using a monoclonal HLA-A2 specific antibody conjugated to
alexa 888 (Serotec). Transduced KG-1 were washed with ice-cold PBS and incubated at
37°C or 4°C for 90 minutes. Cells were then fixed with 2% parafomaldehyde (PFA) and
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plated onto poly-L-lysine coated coverslips. The remaining fluorescence at the cell surface
following incubation at 37°C was analyzed by confocal microscopy (Leica).

4.15 APC/T-cell conjugates
KG-1 cells induced to express WT-A2/GFP or Δ7-A2/GFP fusion proteins were
pulsed with MART-1 peptide (20nM) for 2 hrs at room temperature. Cells were then coincubated with MART-1 specific T cells at a 1:1 ratio, plated in 48 well plates for 2hrs in
order to visualize KG-1/T-cell cluster formation using light microscopy. The mixture of
KG-1 cells and MART-1 specific T cells was also plated onto poly-L-lysine-coated
coverslips and incubated at 37°C for up to 2hrs. The mixture of cells were then fixed using
2% PFA (Fisher) and stained with anti-CD3-δ (6B10.2, BD Biosciences) mAb conjugated
to alexa 647 on ice in order to label MART-1 specific T cells. KG-1/MART-1 T-cell
conjugates were evaluated by confocal microscopy using a 60X oil objective. Z-stacks of
with 20 planes and 2μM spacing between each plane were collected for each image. KG1/MART-1 T-cell conjugates were also quantified by visually counting numbers of MART1 specific T cells conjugated to a random collection of 20 to 30 transduced KG-1 cells.
Conjugates were scored only if MART-1 specific T cells were in contact with one KG-1
cell expressing either WT or Δ7 variants of HLA-A2 fused to GFP.

4.16 Statistical analysis
Microsoft Excel was used for graphing and statistical analysis. The Kaplan-Meier
test was used to compare mouse survival between treatment and control groups. A Student
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T test was used to analyze the statistical significance of the results. A p-value of less or
equal to 0.05 was the cut-off to determine significance of the statistics.
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